[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3059
1. Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG: Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol; 2003 Jan;139(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Thalidomide is an anti-inflammatory agent and an immunomodulator that inhibits the production of tumor necrosis factor alpha.
  • There were 29 patients seen at the Department of Dermatology, Wake Forest University School of Medicine (Winston-Salem, NC), who were unresponsive to conventional agents including antimalarial agents, and who started treatment between 1998 and 2000.
  • Twenty-three patients who took the drug for 1 month or more were included in the analysis.
  • CONCLUSIONS: Based on the results of this case series, we believe that thalidomide should be given prime consideration as a treatment for antimalarial drug-resistant interface lesions of LE.
  • [MeSH-major] Dermatologic Agents / administration & dosage. Lupus Erythematosus, Cutaneous / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Thalidomide / administration & dosage


2. Bennett WD, Daviskas E, Hasani A, Mortensen J, Fleming J, Scheuch G: Mucociliary and cough clearance as a biomarker for therapeutic development. J Aerosol Med Pulm Drug Deliv; 2010 Oct;23(5):261-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A number of investigators currently active in using MCC/CC for diagnostic or therapeutic evaluation presented details of their methodologies.
  • Attendees participating in the workshop discussions included those interested in the physiology of MCC/CC, some of who use in vitro or animal methods for its study, pharmaceutical companies developing muco-active therapies, and many who were interested in establishing the methods in their own clinical laboratory.
  • [MeSH-minor] Animals. Biomarkers / metabolism. Disease Progression. Drug Design. Humans

  • MedlinePlus Health Information. consumer health - Cough.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20804426.001).
  • [ISSN] 1941-2703
  • [Journal-full-title] Journal of aerosol medicine and pulmonary drug delivery
  • [ISO-abbreviation] J Aerosol Med Pulm Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


3. Gu H, Unger S, Deng Y: Automated Tecan programming for bioanalytical sample preparation with EZTecan. Assay Drug Dev Technol; 2006 Dec;4(6):721-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated Tecan programming for bioanalytical sample preparation with EZTecan.
  • Based on the sample run list in the Watson Laboratory Information Management System (InnaPhase Corp., Philadelphia, PA), EZTecan can generate a Tecan program for bioanalytical sample preparation, including sample transfer, sample dilution, extraction, and reconstitution.
  • [MeSH-major] Biological Assay / instrumentation. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199510.001).
  • [ISSN] 1540-658X
  • [Journal-full-title] Assay and drug development technologies
  • [ISO-abbreviation] Assay Drug Dev Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Li Y, Zhang JF, Zhang YM, Ma XB: The protective effect of genistein postconditioning on hypoxia/reoxygenation-induced injury in human gastric epithelial cells. Acta Pharmacol Sin; 2009 May;30(5):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanism by which genistein exerts this protection may be via activation of cellular vanilloid receptor subtype 1, resulting in the generation of an endogenous protection substance, CGRP.
  • [MeSH-major] Epithelial Cells / drug effects. Genistein / therapeutic use. Ischemic Preconditioning / methods. Reperfusion Injury / prevention & control. Stomach / blood supply
  • [MeSH-minor] Apoptosis / drug effects. Calcitonin Gene-Related Peptide / metabolism. Cell Hypoxia / drug effects. Cell Line. Cell Survival / drug effects. Humans. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Pharmacol Sci. 1999 Nov;20(11):459-65 [10542446.001]
  • [Cites] J Mol Cell Cardiol. 2007 Jan;42(1):79-87 [17141266.001]
  • [Cites] J Ocul Pharmacol Ther. 2001 Apr;17(2):151-8 [11324982.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Oct;299(1):67-75 [11561064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13396-401 [11606761.001]
  • [Cites] Endocrinology. 2002 Apr;143(4):1495-501 [11897708.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jan;304(1):217-22 [12490594.001]
  • [Cites] Toxicol Sci. 2003 May;73(1):170-81 [12721390.001]
  • [Cites] Regul Pept. 2003 Jun 15;114(1):45-9 [12763639.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H579-88 [12860564.001]
  • [Cites] J Vasc Res. 2003 May-Jun;40(3):276-84 [12902640.001]
  • [Cites] Br J Pharmacol. 2003 Nov;140(6):1077-87 [14530214.001]
  • [Cites] Cardiovasc Res. 2004 Feb 15;61(3):448-60 [14962476.001]
  • [Cites] Acta Pharmacol Sin. 2004 Mar;25(3):306-12 [15000883.001]
  • [Cites] Pharmacol Rev. 1991 Jun;43(2):143-201 [1852779.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]
  • [Cites] Br J Pharmacol. 1997 Jul;121(5):1012-6 [9222561.001]
  • [Cites] Life Sci. 1998;62(4):PL63-9 [9450509.001]
  • [Cites] Jpn J Pharmacol. 1999 Aug;80(4):275-80 [10496326.001]
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):775-82 [16118913.001]
  • [Cites] J Neurophysiol. 2001 Feb;85(2):745-58 [11160509.001]
  • (PMID = 19349965.001).
  • [ISSN] 1745-7254
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 83652-28-2 / Calcitonin Gene-Related Peptide; DH2M523P0H / Genistein
  • [Other-IDs] NLM/ PMC4002816
  •  go-up   go-down


5. Ross TL, Merz WG, Farkosh M, Carroll KC: Comparison of an automated repetitive sequence-based PCR microbial typing system to pulsed-field gel electrophoresis for analysis of outbreaks of methicillin-resistant Staphylococcus aureus. J Clin Microbiol; 2005 Nov;43(11):5642-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of an automated repetitive sequence-based PCR microbial typing system to pulsed-field gel electrophoresis for analysis of outbreaks of methicillin-resistant Staphylococcus aureus.
  • Rapid and sensitive methods for accurate strain delineation are essential for monitoring and preventing transmission of methicillin-resistant Staphylococcus aureus (MRSA).
  • Pulsed-field gel electrophoresis (PFGE) has been the standard technique for strain typing most bacterial species including MRSA.
  • The goal of this study was to compare the performance of the DiversiLab microbial typing system (Bacterial BarCodes, Inc., Houston, TX) (rep-PCR) to that of PFGE for typing MRSA isolates from five well-defined outbreaks.
  • The DiversiLab rep-PCR assay is a rapid, semiautomated method based on PCR amplification of specific regions between noncoding repetitive sequences in the bacterial genome. rep-PCR was performed according to the manufacturer's recommendations, and the results were analyzed and dendrograms were generated using the DiversiLab analysis software (version 2.1.66 a).
  • PFGE was performed and interpreted according to published procedures. rep-PCR results using similarity indices (SI) of 80%, 85%, and 90% were compared to PFGE analysis.
  • In addition, intra- and interrun reproducibility was determined for rep-PCR.
  • Overall, correct assignment to outbreak versus nonoutbreak clusters occurred for 91 of 109 isolates (85% agreement) when using a SI of 85%.
  • For each specific outbreak, concordance between rep-PCR and PFGE ranged from 73% to 100%.
  • There were 18 discrepant results (17%).
  • Fourteen isolates were unique by PFGE, but they were placed in clusters by rep-PCR; the other 4 were placed in clusters different from those assigned by PFGE.
  • Intra- and interrun reproducibility was excellent.
  • Times to results were 12 to 24 h for rep-PCR compared to 2 to 4 days for PFGE.
  • Rapid, standardized results and excellent reproducibility make rep-PCR a valuable tool for use in MRSA investigations.
  • However, since rep-PCR was less discriminatory than PFGE, we recommend that it be used to screen isolates, followed by testing isolates which share the same rep-PCR pattern with a more sensitive method, such as PFGE or multilocus sequence typing.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. METHICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2000 Oct;38(10):3527-33 [11015358.001]
  • [Cites] J Clin Microbiol. 2005 Mar;43(3):1187-92 [15750081.001]
  • [Cites] Clin Microbiol Rev. 2001 Jul;14(3):547-60 [11432813.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3442-5 [11574553.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1574-85 [12682148.001]
  • [Cites] Infect Control Hosp Epidemiol. 2003 May;24(5):362-86 [12785411.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5113-20 [14605147.001]
  • [Cites] J Antimicrob Chemother. 2004 Jan;53(1):74-80 [14657086.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31 [15155210.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2685-93 [15184453.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):4016-24 [15364984.001]
  • [Cites] J Clin Microbiol. 1991 Dec;29(12):2752-7 [1757545.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6823-31 [1762913.001]
  • [Cites] J Infect Dis. 1993 Apr;167(4):850-6 [8450250.001]
  • [Cites] J Clin Microbiol. 1994 Feb;32(2):407-15 [7908673.001]
  • [Cites] J Clin Microbiol. 1995 Mar;33(3):551-5 [7751356.001]
  • [Cites] Clin Lab Med. 1995 Jun;15(2):407-31 [7671580.001]
  • [Cites] J Clin Microbiol. 1995 Sep;33(9):2233-9 [7494007.001]
  • [Cites] J Clin Microbiol. 1996 May;34(5):1193-202 [8727902.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):647-54 [10230355.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1661-9 [10325304.001]
  • [Cites] Am J Infect Control. 2004 Dec;32(8):470-85 [15573054.001]
  • [Cites] J Clin Microbiol. 2005 Jan;43(1):199-207 [15634972.001]
  • [Cites] Microb Drug Resist. 2000 Fall;6(3):189-98 [11144419.001]
  • (PMID = 16272498.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI-02-031
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; Q91FH1328A / Methicillin
  • [Other-IDs] NLM/ PMC1287783
  •  go-up   go-down


6. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT: Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res; 2002 Jan;17(1):101-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells.
  • Osteoblasts secrete a complex extracellular matrix (ECM) containing collagenous and noncollagenous proteins, bone morphogenetic proteins (BMPs), and growth factors.
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. Extracellular Matrix / metabolism. Mitogen-Activated Protein Kinases / metabolism. Osteoblasts / cytology. Osteoblasts / metabolism. Transforming Growth Factor beta
  • [MeSH-minor] 3T3 Cells. Animals. Ascorbic Acid / pharmacology. Base Sequence. Bone Morphogenetic Protein 2. Bone Morphogenetic Protein 4. Bone Morphogenetic Protein 7. Cell Differentiation. Gene Expression / drug effects. Integrin-Binding Sialoprotein. Mice. Osteocalcin / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sialoglycoproteins / genetics. Signal Transduction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11771655.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE 11723
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bmp2 protein, mouse; 0 / Bmp4 protein, mouse; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / Ibsp protein, mouse; 0 / Integrin-Binding Sialoprotein; 0 / RNA, Messenger; 0 / Sialoglycoproteins; 0 / Transforming Growth Factor beta; 104982-03-8 / Osteocalcin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


7. Dong Y, Cao BY, Wang J, Ding DL, Han ZF, Shi JR: Effects of Erlong Zuoci pill and its disassembled prescriptions on gentamicin-induced ototoxicity model in vitro. Chin J Integr Med; 2010 Jun;16(3):258-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Gentamicins / toxicity. Organ of Corti / drug effects. Organ of Corti / pathology. Prescriptions
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Hair Cells, Auditory, Inner / drug effects. Hair Cells, Auditory, Inner / pathology. Hair Cells, Auditory, Outer / drug effects. Hair Cells, Auditory, Outer / pathology. Mice. Tablets

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):46-54 [12583992.001]
  • [Cites] Hear Res. 2008 Feb;236(1-2):52-60 [18207679.001]
  • [Cites] J Neurochem. 2009 Mar;108(5):1226-36 [19141081.001]
  • [Cites] Zhongguo Zhong Xi Yi Jie He Za Zhi. 1995 Jul;15(7):422-3 [7580066.001]
  • (PMID = 20694782.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Gentamicins; 0 / Tablets; 0 / erlong zuoci
  •  go-up   go-down


8. Wada Y, Saitoh H, Nakasone I, Yamane N: [Application of DNA-DNA hybridization, DDH MYCOBACTERIA 'Kyokuto' to species-identification of mycobacteria grown in Middlebrook 7H9 broth]. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2000 Aug;11(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A colorimetric DNA-DNA hybridization for the genetic identification of mycobacteria, DDH MYCOBACTERIA 'KYOKUTO' (Kyokuto Pharmaceuticals, Tokyo) was evaluated for the clinical isolates of mycobacteria grown in Middlebrook 7H9 broth of MB/BacT (Organon Teknika, Durham, NC, U.S.A.).
  • [MeSH-major] Bacteriological Techniques. Culture Media. Mycobacterium / isolation & purification. Nucleic Acid Hybridization

  • Hazardous Substances Data Bank. ACETONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11004711.001).
  • [ISSN] 0915-1753
  • [Journal-full-title] Rinshō Biseibutsu Jinsoku Shindan Kenkyūkai shi = JARMAM : Journal of the Association for Rapid Method and Automation in Microbiology
  • [ISO-abbreviation] Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Culture Media; 0 / DNA, Bacterial; 1364PS73AF / Acetone
  •  go-up   go-down


9. Morgan EA, Henrich TJ, Jarell AD, Shieh WJ, Zaki SR, Marty FM, Thorner AR, Milner DA, Velazquez EF: Infectious granulomatous dermatitis associated with Rothia mucilaginosa bacteremia: A case report. Am J Dermatopathol; 2010 Apr;32(2):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Actinomycetales Infections / complications. Actinomycetales Infections / microbiology. Biopsy. Drug Therapy. Humans. Immunocompromised Host. Leukemia, Myeloid, Acute / drug therapy. Male. Middle Aged. Opportunistic Infections / complications. Opportunistic Infections / microbiology. Skin / microbiology. Skin / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940746.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ozyazgan S, Kutluata N, Afşar S, Ozdaş SB, Akkan AG: Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology; 2005 Jun;74(3):119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the vascular effects of glucagon-like peptide-1 (GLP-1) and Exendin-4 in type 2 diabetic rat aortae.
  • GLP-1 and (partially) Exendin-4 treatment could improve the increased blood glucose level and normalize the altered vascular tone in type 2 diabetic rats.
  • [MeSH-major] Diabetes Mellitus, Experimental / drug therapy. Peptide Fragments / pharmacology. Peptides / pharmacology. Vasodilator Agents / pharmacology. Venoms / pharmacology
  • [MeSH-minor] Animals. Aorta, Thoracic / drug effects. Aorta, Thoracic / physiology. Blood Glucose / drug effects. Dose-Response Relationship, Drug. Female. Glucagon. Glucagon-Like Peptide 1. Glucagon-Like Peptides. In Vitro Techniques. Male. Muscle Relaxation / drug effects. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / physiology. Niacinamide. Oxidative Stress / drug effects. Rats. Rats, Wistar. Streptozocin

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. GLUCAGON .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 S. Karger AG, Basel
  • (PMID = 15746570.001).
  • [ISSN] 0031-7012
  • [Journal-full-title] Pharmacology
  • [ISO-abbreviation] Pharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Peptide Fragments; 0 / Peptides; 0 / Vasodilator Agents; 0 / Venoms; 107444-51-9 / glucagon-like peptide 1 (7-36); 25X51I8RD4 / Niacinamide; 5W494URQ81 / Streptozocin; 62340-29-8 / Glucagon-Like Peptides; 89750-14-1 / Glucagon-Like Peptide 1; 9007-92-5 / Glucagon; 9P1872D4OL / exenatide
  •  go-up   go-down


11. Sharquie KE, Noaimi AA, Saleh BO, Anbar ZN: The frequency of 21-alpha hydroxylase enzyme deficiency and related sex hormones in Iraqi healthy male subjects versus patients with acne vulgaris. Saudi Med J; 2009 Dec;30(12):1547-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of 21-alpha hydroxylase enzyme deficiency and related sex hormones in Iraqi healthy male subjects versus patients with acne vulgaris.
  • OBJECTIVE: To find out the frequency of nonclassical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency among Iraqi healthy male individuals versus male patients with acne vulgaris.
  • METHODS: This case-control study and single-center examination of hormone levels in a cohort of volunteers was conducted in the Department of Dermatology, Baghdad Teaching Hospital, and in the Physiological Chemistry Department of the College of Medicine, Baghdad University, Baghdad, Iraq, from September 2007 to February 2008.
  • RESULTS: The frequency of 21-hydroxylase enzyme deficiency in healthy male subjects was 1:43 (2.3%), while in male patients with acne vulgaris, this was 6:43 (13.95%).
  • Serum 17-hydroxyprogesterone (OHP) levels were statistically and significantly elevated in male patients with acne vulgaris compared with healthy male controls (p=0.020).
  • The serum total cortisol level was significantly reduced in patients with acne vulgaris in comparison with that of healthy controls (p=0.022).
  • CONCLUSION: These results support the necessity of inclusion of the 21-alpha hydroxylase enzyme activity (serum 17-OHP level) screening test in acne patients.
  • [MeSH-major] 17-alpha-Hydroxyprogesterone / blood. Acne Vulgaris / enzymology. Hydrocortisone / blood. Steroid 21-Hydroxylase / metabolism

  • MedlinePlus Health Information. consumer health - Acne.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. 17ALPHA-HYDROXYPROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936418.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 68-96-2 / 17-alpha-Hydroxyprogesterone; EC 1.14.99.10 / Steroid 21-Hydroxylase; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


12. Kigami Y, Kobayashi H, Umeoka S, Emoto T, Akuta K: [Early effect of intra-arterial chemotherapy combined with degradable starch microspheres for malignant hepatic tumors]. Gan To Kagaku Ryoho; 2003 Jan;30(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The necrotic effect of embolization was classified as CR, PR, NC, and PD after 9, 41, 10, and 2 treatments, respectively, in the patients with metastatic carcinoma of the liver and after 4, 6, 6, and 3 treatments, respectively, in the patients with hepatocellular carcinoma.
  • Therefore, blocking of blood flow seemed to contribute more to the response than enhancement of the efficacy of the anticancer agents.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12557709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / degradable starch microspheres; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 9005-25-8 / Starch
  •  go-up   go-down


13. Lü X, Ruishu W: [Effect of magnesium supplementation on NO and NOS subtypes in cultured human umbilical vein endothelial Cells]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan;34(1):138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of magnesium supplementation on NO and NOS subtypes in cultured human umbilical vein endothelial Cells].
  • This study inquired into the effect of Mg2+ on nitric oxide (NO) and nitric oxide synthase (NOS) in cultured human umbilical vein endothelial cells.
  • CONCLUSION: The antioxidant mechanisms of magnesium are probably involved in the regulation of cellular transcription factors and of NOS subtypes.
  • [MeSH-minor] Cells, Cultured. Dose-Response Relationship, Drug. Endothelial Cells / metabolism. Humans. Nitric Oxide Synthase Type II. Nitric Oxide Synthase Type III. Umbilical Veins / cytology. Umbilical Veins / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600206.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antioxidants; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III; I38ZP9992A / Magnesium
  •  go-up   go-down


14. Salina EG, Vostroknutova GN, Shleeva MO, Kaprel'iants AS: [Cell-cell interactions during formation and reactivation of "nonculturable" mycobacteria]. Mikrobiologiia; 2006 Jul-Aug;75(4):502-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NC mycobacteria have attracted particular interest due to the assumption that the latent form of tuberculosis is associated with the conversion of its causative agent, Mycobacterium tuberculosis, into the NC state.
  • Special attention has been paid to the secreted Rpf family proteins, which belong to peptidoglycan hydrolases and participate in the resuscitation of NC mycobacteria.
  • [MeSH-minor] Bacterial Proteins / physiology. Culture Media. Cytokines / physiology. Mycobacterium Infections / microbiology. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17025176.001).
  • [ISSN] 0026-3656
  • [Journal-full-title] Mikrobiologiia
  • [ISO-abbreviation] Mikrobiologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / Cytokines; 0 / resuscitation-promoting factor, bacteria
  •  go-up   go-down


15. Zhang S, Li H, Xu H, Yang SJ: [Effect of gross saponins of Tribulus terrestris on cardiocytes impaired by adriamycin]. Yao Xue Xue Bao; 2010 Jan;45(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / toxicity. Apoptosis / drug effects. Aspartate Aminotransferases / metabolism. Caspase 3 / metabolism. Cell Survival / drug effects. Cells, Cultured. Creatine Kinase / metabolism. L-Lactate Dehydrogenase / metabolism. Malondialdehyde / metabolism. Nitric Oxide / metabolism. Rats. Rats, Wistar. Superoxide Dismutase / metabolism

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351446.001).
  • [ISSN] 0513-4870
  • [Journal-full-title] Yao xue xue bao = Acta pharmaceutica Sinica
  • [ISO-abbreviation] Yao Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Saponins; 31C4KY9ESH / Nitric Oxide; 4Y8F71G49Q / Malondialdehyde; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.15.1.1 / Superoxide Dismutase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.7.3.2 / Creatine Kinase; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


16. Lopes CL, Teles SA, Espírito-Santo MP, Lampe E, Rodrigues FP, Motta-Castro AR, Marinho TA, Reis NR, Silva AM, Martins RM: Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev Saude Publica; 2009 Aug;43 Suppl 1:43-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil.
  • METHODS: Study conducted including 691 drug users attending 26 charitable, private and public drug treatment centers in Goiânia and Campo Grande, central-western Brazil, between 2005 and 2006.
  • The multivariate analysis of risk factors revealed that age over 30 years and injecting drug use were associated with HCV infection.
  • CONCLUSIONS: The results show a high prevalence of HCV infection and predominance of subtype 1a among drug users in Brazil.
  • In addition, injecting drug use was a major risk factor associated with HCV infection.
  • [MeSH-major] Drug Users / statistics & numerical data. Hepacivirus / genetics. Hepatitis C / epidemiology. Substance Abuse, Intravenous / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669064.001).
  • [ISSN] 1518-8787
  • [Journal-full-title] Revista de saúde pública
  • [ISO-abbreviation] Rev Saude Publica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / RNA, Viral
  •  go-up   go-down


17. Nowak A, Libudzisz Z: Ability of probiotic Lactobacillus casei DN 114001 to bind or/and metabolise heterocyclic aromatic amines in vitro. Eur J Nutr; 2009 Oct;48(7):419-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Analysis of Variance. Cells, Cultured. Chromatography, High Pressure Liquid. Colony Count, Microbial. Comet Assay. DNA Damage / drug effects. Hydrogen-Ion Concentration. Imidazoles / analysis. Imidazoles / metabolism. Imidazoles / pharmacology. Quinolines / analysis. Quinolines / metabolism. Quinolines / pharmacology. Quinoxalines / analysis. Quinoxalines / metabolism. Quinoxalines / pharmacology. Spectrophotometry, Ultraviolet. Time Factors

  • Hazardous Substances Data Bank. 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1994 Dec 1;311(2):239-48 [7526189.001]
  • [Cites] Food Chem Toxicol. 1997 Jun;35(6):535-45 [9225011.001]
  • [Cites] Curr Issues Intest Microbiol. 2000 Mar;1(1):13-24 [11709850.001]
  • [Cites] Anal Bioanal Chem. 2007 Sep;389(1):139-46 [17546447.001]
  • [Cites] Mutat Res. 2007 Mar 1;616(1-2):90-4 [17161439.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Jul;35(1):31-8 [12142807.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):274-84 [17368226.001]
  • [Cites] Trends Microbiol. 2006 Feb;14(2):86-91 [16406528.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12 (9):940-4 [14504209.001]
  • [Cites] Mutat Res. 2007 Jun 15;630(1-2):14-9 [17392018.001]
  • [Cites] Mutat Res. 1998 Oct 12;421(1):65-72 [9748508.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):260-7 [16519996.001]
  • [Cites] J Nutr. 2007 Mar;137(3 Suppl 2):751S-5S [17311972.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1120-5 [16775169.001]
  • [Cites] Mutat Res. 1996 Jun 12;363(2):89-96 [8676929.001]
  • [Cites] Mutat Res. 2000 Jul;463(1):53-101 [10838209.001]
  • [Cites] Toxicol Lett. 2007 Feb 5;168(3):219-27 [17174486.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):136-42 [17354224.001]
  • [Cites] Exp Cell Res. 1988 Mar;175(1):184-91 [3345800.001]
  • [Cites] Mutat Res. 1993 Feb;298(4):247-53 [7678160.001]
  • [Cites] Mutat Res. 1998 Feb 2;397(2):169-82 [9541641.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:137-44 [12351153.001]
  • [Cites] Mutat Res. 2000 Aug 21;469(1):135-45 [10946250.001]
  • [Cites] Mutat Res. 1999 Jul 15;443(1-2):149-56 [10415438.001]
  • [Cites] Carcinogenesis. 1998 Feb;19(2):359-63 [9498289.001]
  • [Cites] Appl Environ Microbiol. 2005 Sep;71(9):5116-23 [16151094.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):299-313 [15123071.001]
  • [Cites] Food Chem Toxicol. 1998 Apr;36(4):279-87 [9651044.001]
  • [Cites] Eur J Nutr. 2004 Jun;43 Suppl 2:II118-II173 [15221356.001]
  • [Cites] Mol Microbiol. 2006 Mar;59(6):1639-50 [16553872.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Mar 25;802(1):211-5 [15036013.001]
  • [Cites] Mutat Res. 2005 Dec 11;591(1-2):276-89 [16095630.001]
  • [Cites] J Agric Food Chem. 2006 May 3;54(9):3454-61 [16637707.001]
  • [Cites] Mutat Res. 1990 May;238(3):209-21 [2160606.001]
  • [Cites] World J Gastroenterol. 2006 Sep 14;12(34):5447-57 [17006980.001]
  • [Cites] Food Chem Toxicol. 2007 Apr;45(4):667-75 [17141386.001]
  • [Cites] Carcinogenesis. 1995 Jan;16(1):39-52 [7834804.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):175S-182S [17182822.001]
  • [Cites] Food Chem Toxicol. 2006 Apr;44(4):484-92 [16226366.001]
  • [Cites] Rev Esp Enferm Dig. 2003 Mar;95(3):186-90, 181-5 [12760708.001]
  • [Cites] Biosci Biotechnol Biochem. 1998 Feb;62(2):197-200 [9532774.001]
  • (PMID = 19448966.001).
  • [ISSN] 1436-6215
  • [Journal-full-title] European journal of nutrition
  • [ISO-abbreviation] Eur J Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-amino-1-methyl-6-phenyl-1H-imidazo(4,5-b)pyridine; 0 / 2-amino-3-methyl-3H-imidazo(4,5-f)quinoline; 0 / Amines; 0 / Aminopyridines; 0 / Heterocyclic Compounds; 0 / Imidazoles; 0 / Mutagens; 0 / Quinolines; 0 / Quinoxalines; 77500-04-0 / 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline
  •  go-up   go-down


18. Chen XF, Lin WD, Lu SL, Xie T, Ge K, Shi YQ, Zou JJ, Liu ZM, Liao WQ: Mechanistic study of endogenous skin lesions in diabetic rats. Exp Dermatol; 2010 Dec;19(12):1088-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The impact of exposure to (AGE) advanced glycation end products-modified human serum albumin (AGE-HSA) on epidermal cells and ECV304 cells was evaluated in cell culture experiments.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line. Cell Proliferation / drug effects. Cell Survival / drug effects. Cells, Cultured. Endothelial Cells / drug effects. Endothelial Cells / pathology. Epidermis / pathology. Epithelial Cells / drug effects. Epithelial Cells / pathology. Glucose / metabolism. Glutathione / blood. Glycosylation End Products, Advanced / blood. Glycosylation End Products, Advanced / metabolism. Glycosylation End Products, Advanced / pharmacology. Male. Malondialdehyde / blood. Microvessels / pathology. Oxidative Stress. Rats. Rats, Sprague-Dawley. Serum Albumin / pharmacology

  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20701629.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / Serum Albumin; 0 / advanced glycation end products-human serum albumin; 4Y8F71G49Q / Malondialdehyde; GAN16C9B8O / Glutathione; IY9XDZ35W2 / Glucose
  •  go-up   go-down


19. Chen S, Ganguli S, Hunt CA: An agent-based computational approach for representing aspects of in vitro multi-cellular tumor spheroid growth. Conf Proc IEEE Eng Med Biol Soc; 2004;1:691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An agent-based computational approach for representing aspects of in vitro multi-cellular tumor spheroid growth.
  • We have implemented an agent-based computational approach to study the macro- and micro- behaviors of avascular tumor spheroids during growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17271771.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Chello M, Carassiti M, Agrò F, Mastroroberto P, Pugliese G, Colonna D, Covino E: Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth; 2004 Oct;18(5):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cardiopulmonary Bypass / methods. Cell Adhesion Molecules / blood. Cell Adhesion Molecules / drug effects. Coronary Artery Bypass / methods. Simvastatin / pharmacology
  • [MeSH-minor] Anticholesteremic Agents / pharmacology. Case-Control Studies. E-Selectin / blood. E-Selectin / drug effects. Female. Humans. Intercellular Adhesion Molecule-1 / blood. Intercellular Adhesion Molecule-1 / drug effects. Male. Middle Aged. Postoperative Complications / prevention & control. Time Factors. Treatment Outcome. Vascular Cell Adhesion Molecule-1 / blood. Vascular Cell Adhesion Molecule-1 / drug effects

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578471.001).
  • [ISSN] 1053-0770
  • [Journal-full-title] Journal of cardiothoracic and vascular anesthesia
  • [ISO-abbreviation] J. Cardiothorac. Vasc. Anesth.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Cell Adhesion Molecules; 0 / E-Selectin; 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1; AGG2FN16EV / Simvastatin
  •  go-up   go-down


21. Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer; 2007;6:60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the oncomiRs expression profiling of human malignancies has also identified a number of diagnostic and prognostic cancer signatures.
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Microarray Analysis. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):974-8 [15944714.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):497-508 [16728577.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Mol Cancer. 2006;5:29 [16854228.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):845-50 [16969504.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4677-84 [16966691.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] RNA. 2007 Jan;13(1):151-9 [17105992.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;313:73-84 [17217039.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2130-4 [17135268.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Mol Cancer. 2007;6:5 [17222355.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8256-64 [17220301.001]
  • [Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]
  • [Cites] Mol Cancer. 2007;6:25 [17407558.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):7957-62 [17483472.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):12-7 [17475218.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Expert Rev Proteomics. 2007 Jun;4(3):401-10 [17552924.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4148-57 [17260024.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):6099-105 [17384677.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):205-11 [17709800.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):745-6 [15944682.001]
  • (PMID = 17894887.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC2098778
  •  go-up   go-down


22. Wan J, Sun W, Li X, Ying W, Dai J, Kuai X, Wei H, Gao X, Zhu Y, Jiang Y, Qian X, He F: Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics; 2006 May;6(9):2886-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel member of the coronavirus, SARS-CoV, has been identified as the causative agent.
  • To enrich the low-abundance proteins in human plasma, two highly abundant proteins, albumin and IgG, were first removed.
  • By comparing the plasma proteins of SARS patients with those of a normal control group, several proteins with a significant alteration were found.
  • The up-regulated proteins were identified as alpha-1 acid glycoprotein, haptoglobin, alpha-1 anti-chymotrypsin and fetuin.
  • The down-regulated proteins were apolipoprotein A-I, transferrin and transthyretin.
  • Most of the proteins showed significant changes (up- or down-regulated) in the progressive phase of disease, and there was a trend back to normal level during the convalescent phase.
  • Among these proteins, the alterations of fetuin and anti-chymotrypsin were further confirmed by Western blotting.
  • Since all the up-regulated proteins identified above are well-known inflammation inhibitors, these results strongly suggest that the body starts inflammation inhibition to sustain the inflammatory response balance in the progression of SARS.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649161.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Haptoglobins; 0 / Orosomucoid; 0 / Prealbumin; 0 / alpha 1-Antichymotrypsin; 0 / alpha-Fetoproteins
  •  go-up   go-down


23. Almushayt A, Narayanan K, Zaki AE, George A: Dentin matrix protein 1 induces cytodifferentiation of dental pulp stem cells into odontoblasts. Gene Ther; 2006 Apr;13(7):611-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dentin matrix protein 1 (DMP1) is one of the dentin noncollagenous extracellular matrix proteins that has been implicated in regulation of mineralization.
  • Collagen matrix impregnated with recombinant DMP1 was implanted directly in Group 1, while calcium hydroxide, a commonly used pulp-capping agent was implanted in group 2, collagen matrix that was not impregnated with rDMP1 was implanted directly in group 3, which served as control.
  • [MeSH-major] Dental Caries / therapy. Dental Papilla / metabolism. Extracellular Matrix Proteins / administration & dosage. Genetic Therapy / methods. Odontoblasts / pathology. Phosphoproteins / administration & dosage
  • [MeSH-minor] Animals. Cell Differentiation. Collagen / metabolism. Dental Pulp Exposure. Dentinogenesis. Immunohistochemistry / methods. Male. Microscopy, Confocal. Rats. Rats, Sprague-Dawley. Recombinant Proteins / administration & dosage. Recombinant Proteins / genetics. Recombinant Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319946.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE11657
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dmp1 protein, rat; 0 / Extracellular Matrix Proteins; 0 / Phosphoproteins; 0 / Recombinant Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


24. Grieve DJ, Avella MA, Elliott J, Botham KM: The interaction between oxidised chylomicron remnants and the aorta of rats fed a normocholesterolaemic or hypercholesterolaemic diet. J Vasc Res; 2000 Jul-Aug;37(4):265-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incubation of aortic rings taken from normocholesterolaemic animals with oxidised (by treatment with copper sulphate) chylomicron remnant particles resulted in a reduction in both vessel sensitivity and maximum percent relaxation in response to carbachol (CCh) and ATP, without affecting responses to A23187 and S-nitroso-N-acetylpenicillamine (SNAP).
  • Perfusion of the aorta of these hypercholesterolaemic rats for 2 h with (125)I-labelled oxidised chylomicron remnants showed that significantly greater amounts of lipoprotein became associated with the artery wall, as compared to control normocholesterolaemic animals.
  • [MeSH-minor] Animals. Carbachol / pharmacology. Cholesterol / blood. In Vitro Techniques. Lipoproteins / metabolism. Male. Oxidation-Reduction. Perfusion. Phenylephrine / pharmacology. Rats. Reference Values. Vasoconstriction / drug effects. Vasoconstriction / physiology. Vasoconstrictor Agents / pharmacology. Vasodilation / drug effects

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965225.001).
  • [ISSN] 1018-1172
  • [Journal-full-title] Journal of vascular research
  • [ISO-abbreviation] J. Vasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cholesterol, Dietary; 0 / Chylomicrons; 0 / Lipoproteins; 0 / Peptide Fragments; 0 / Vasoconstrictor Agents; 1WS297W6MV / Phenylephrine; 8Y164V895Y / Carbachol; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


25. de Filippis AM, Nogueira RM, Schatzmayr HG, Tavares DS, Jabor AV, Diniz SC, Oliveira JC, Moreira E, Miagostovich MP, Costa EV, Galler R: Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus. J Med Virol; 2002 Dec;68(4):620-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seroconversion, virus isolation, histopathological and immunohistochemical findings, and reverse transcription-polymerase chain reaction (RT-PCR) identified yellow fever virus (YFV) as the etiological agent responsible for the outbreak.


26. Monteiro-Riviere NA, Inman AO, Zhang LW: Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol Appl Pharmacol; 2009 Jan 15;234(2):222-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report that classical dye-based assays such as MTT and neutral red (NR) that determine cell viability produce invalid results with some NM (nanomaterials) due to NM/dye interactions and/or NM adsorption of the dye/dye products.
  • In this study, human epidermal keratinocytes (HEK) were exposed in vitro to CB, SWCNT, C(60), nC(60), and QD to assess viability with calcein AM (CAM), Live/Dead (LD), NR, MTT, Celltiter 96 AQueous One (96 AQ), alamar Blue (aB), Celltiter-Blue (CTB), CytoTox Onetrade mark (CTO), and flow cytometry.
  • Results of the dye-based assays varied a great deal, depending on the interactions of the dye/dye product with the carbon nanomaterials (CNM).
  • [MeSH-minor] Cell Line. Cell Survival / drug effects. Drug Evaluation, Preclinical. Flow Cytometry. Fluoresceins. Fluorescent Dyes. Humans. Keratinocytes / drug effects. Light. Microscopy, Electron, Transmission. Oxazines. Quantum Dots. Scattering, Radiation. Spectrophotometry, Ultraviolet. Tetrazolium Salts. Thiazoles. Trypan Blue. Xanthenes

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. Trypan blue .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983864.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / Fluorescent Dyes; 0 / Oxazines; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Xanthenes; 148504-34-1 / calcein AM; 1FN9YD6968 / resazurin; 298-93-1 / thiazolyl blue; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


27. Song H, Xin XY, Xiao F, Wang DT, Han X, Guo HL: [Influence of survivin gene repression by RNA interference on the radiosensitivity and chemosensitivity to cisplatin of cervical cancer cell HeLa]. Zhonghua Fu Chan Ke Za Zhi; 2006 Aug;41(8):554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Apoptosis / drug effects. Cisplatin / pharmacology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. RNA Interference. Radiation Tolerance / genetics
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Caspase 3 / metabolism. Cell Survival / drug effects. Cell Survival / genetics. Cell Survival / radiation effects. Down-Regulation. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / radiation effects. HeLa Cells. Humans. Inhibitor of Apoptosis Proteins. Inhibitory Concentration 50. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • Genetic Alliance. consumer health - Cervical cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083843.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.4.22.- / Caspase 3; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Jacobs F, Thierens H, Piepsz A, Bacher K, Van de Wiele C, Ham H, Dierckx RA, European Association of Nuclear Medicine: Optimised tracer-dependent dosage cards to obtain weight-independent effective doses. Eur J Nucl Med Mol Imaging; 2005 May;32(5):581-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The aim of this study was twofold: firstly, to determine whether the European Association of Nuclear Medicine (EANM) dosage card results in weight-independent effective doses or weight-independent count rates; secondly, to determine whether one dosage card is sufficient for 95 different radiopharmaceuticals, and, if not, how many cards we reasonably need to take into account inter-tracer variability.

  • MedlinePlus Health Information. consumer health - Body Weight.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 1990;17(3-4):127-9 [2279492.001]
  • [Cites] Ann ICRP. 1983;11-13:1-1250 [6670795.001]
  • [Cites] J Nucl Med. 1996 Mar;37(3):538-46 [8772664.001]
  • (PMID = 15619101.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes
  •  go-up   go-down


29. Calloni GW, Le Douarin NM, Dupin E: High frequency of cephalic neural crest cells shows coexistence of neurogenic, melanogenic, and osteogenic differentiation capacities. Proc Natl Acad Sci U S A; 2009 Jun 2;106(22):8947-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Cell Differentiation. Core Binding Factor Alpha 1 Subunit / genetics. Core Binding Factor Alpha 1 Subunit / metabolism. Gene Expression / drug effects. Hedgehog Proteins / metabolism. Hedgehog Proteins / pharmacology. Oncogene Proteins / genetics. Quail. Trans-Activators / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1993 Jul;207(1):171-82 [7686497.001]
  • [Cites] Anat Embryol (Berl). 1992 Jul;186(2):107-24 [1510240.001]
  • [Cites] Acta Orthop Scand Suppl. 1995 Oct;266:61-5 [8553864.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] FEBS Lett. 1997 Mar 10;404(2-3):319-23 [9119087.001]
  • [Cites] Cell. 1997 May 30;89(5):747-54 [9182762.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Cell. 1997 May 30;89(5):765-71 [9182764.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 18;237(2):465-9 [9268735.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Mech Dev. 1999 Feb;80(2):159-70 [10072783.001]
  • [Cites] Nat Genet. 1999 May;22(1):85-9 [10319868.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Genes Dev. 1999 Aug 15;13(16):2072-86 [10465785.001]
  • [Cites] Development. 2005 Sep;132(17):3977-88 [16049113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14665-70 [16203988.001]
  • [Cites] Development. 2006 Aug;133(16):3231-44 [16854976.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6197-208 [16880529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11607-12 [16868080.001]
  • [Cites] Adv Exp Med Biol. 2006;589:96-119 [17076277.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2411-8 [17442891.001]
  • [Cites] Development. 2007 Sep;134(17):3133-44 [17670790.001]
  • [Cites] Dev Dyn. 2007 Dec;236(12):3242-54 [17823935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19879-84 [18077420.001]
  • [Cites] Ann N Y Acad Sci. 2007 Nov;1116:59-64 [18083921.001]
  • [Cites] Dev Biol. 2008 Jun 1;318(1):52-64 [18436202.001]
  • [Cites] Cell Cycle. 2008 Apr 15;7(8):1013-9 [18414040.001]
  • [Cites] Curr Biol. 1999 Nov 18;9(22):1304-14 [10574760.001]
  • [Cites] Cell. 2000 Jan 7;100(1):157-68 [10647940.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):295-304 [11160153.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2085-94 [11493644.001]
  • [Cites] Nat Neurosci. 2003 Jan;6(1):21-7 [12469128.001]
  • [Cites] Nature. 2003 May 15;423(6937):326-31 [12748650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9360-5 [12878728.001]
  • [Cites] Neuron. 2003 Sep 11;39(6):937-50 [12971894.001]
  • [Cites] Development. 2003 Dec;130(23):5681-93 [14522876.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):210-22 [14980515.001]
  • [Cites] Development. 2004 Mar;131(6):1309-18 [14973297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4495-500 [15070746.001]
  • [Cites] Dev Biol. 2004 May 1;269(1):55-69 [15081357.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):937-51 [15107405.001]
  • [Cites] J Clin Invest. 2004 Aug;114(4):485-94 [15314685.001]
  • [Cites] J Cell Biol. 2004 Aug 30;166(5):673-84 [15337776.001]
  • [Cites] Dev Biol. 2004 Oct 1;274(1):188-200 [15355797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(14):5325-9 [2455901.001]
  • [Cites] Cell Tissue Res. 1988 Nov;254(2):317-30 [3197089.001]
  • [Cites] Biol Rev Camb Philos Soc. 1990 Aug;65(3):277-373 [2205303.001]
  • [Cites] Dev Biol. 1991 Nov;148(1):95-106 [1936578.001]
  • [Cites] Development. 1991 May;112(1):301-5 [1769335.001]
  • [Cites] Development. 1993 Feb;117(2):409-29 [8330517.001]
  • (PMID = 19447928.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC2690024
  •  go-up   go-down


30. Bhatt K, Zhou L, Mi QS, Huang S, She JX, Dong Z: MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med; 2010 Sep-Oct;16(9-10):409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cisplatin / toxicity. Kidney / drug effects. Kidney / pathology. MicroRNAs / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line. Cell Survival / drug effects. Gene Expression Regulation / drug effects. Male. Mice. Mice, Inbred C57BL

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2000 May;278(5):F726-36 [10807584.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Oct;285(4):F610-8 [12865254.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jul;302(1):8-17 [12065694.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43377-88 [12218054.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Mar;284(3):F488-97 [12419774.001]
  • [Cites] Semin Nephrol. 2003 Sep;23(5):460-4 [13680535.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Feb;286(2):F378-84 [12965891.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Mar;286(3):F572-80 [14612380.001]
  • [Cites] Arch Toxicol. 2004 Mar;78(3):147-55 [14551673.001]
  • [Cites] Am J Physiol. 1996 Apr;270(4 Pt 2):F700-8 [8967349.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 2):F1211-6 [8997395.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Dec;287(6):F1140-7 [15315938.001]
  • [Cites] Kidney Int. 2004 Dec;66(6):2202-13 [15569309.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F166-74 [15701814.001]
  • [Cites] J Am Soc Nephrol. 2005 Jul;16(7):1985-92 [15901768.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31230-9 [15983031.001]
  • [Cites] Oncogene. 2006 Jul 6;25(29):4056-66 [16491117.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2636-45 [17130128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3432-7 [17360662.001]
  • [Cites] Biochem Pharmacol. 2007 May 1;73(9):1499-510 [17291459.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jul;322(1):8-15 [17400889.001]
  • [Cites] Kidney Int. 2007 Jul;72(1):53-62 [17410096.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • [Cites] Cell Cycle. 2007 Jul 1;6(13):1586-93 [17554199.001]
  • [Cites] Curr Biol. 2007 Aug 7;17(15):1298-307 [17656095.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 [17875987.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Oct;293(4):F1282-91 [17670903.001]
  • [Cites] J Biol Chem. 2008 Mar 7;283(10):6572-83 [18162465.001]
  • [Cites] Kidney Int. 2008 May;73(9):994-1007 [18272962.001]
  • [Cites] Kidney Int. 2008 Sep;74(5):631-40 [18509315.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5959-74 [18836476.001]
  • [Cites] Life Sci. 2008 Oct 10;83(15-16):550-6 [18761355.001]
  • [Cites] J Am Soc Nephrol. 2008 Nov;19(11):2159-69 [18776119.001]
  • [Cites] J Am Soc Nephrol. 2008 Nov;19(11):2150-8 [18776121.001]
  • [Cites] J Am Soc Nephrol. 2008 Nov;19(11):2069-75 [18832437.001]
  • [Cites] Nat Cell Biol. 2009 Mar;11(3):228-34 [19255566.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2009 Jul;18(4):317-23 [19424061.001]
  • [Cites] Oncogene. 2009 Jun 25;28(25):2419-24 [19421141.001]
  • [Cites] Nat Cell Biol. 2009 Jul;11(7):881-9 [19543271.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Jul;4(7):1255-66 [19581401.001]
  • [Cites] Kidney Int. 2009 Aug;76(3):277-85 [19436334.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):858-65 [11912244.001]
  • (PMID = 20386864.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN34 microRNA, mouse; 0 / MicroRNAs; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Tomizawa K, Sugano K, Yamada H, Horii I: Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J Toxicol Sci; 2006 Oct;31(4):315-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of the principal requisites of toxicity screening methods in drug discovery are their ease to perform and high throughput, as well as the possibility to predict the occurrence of clinical events.
  • Phospholipidosis is one of the toxicities often induced by potential drugs.
  • The ClogP - NC plot differentiated positive and negative compounds with more than 98% accuracy (62/63), indicating its usefulness in drug discovery.
  • [MeSH-minor] Animals. Cells, Cultured. Hepatocytes / drug effects. Hepatocytes / metabolism. Hepatocytes / ultrastructure. Inclusion Bodies / drug effects. Male. Rats

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077586.001).
  • [ISSN] 0388-1350
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Phospholipids
  •  go-up   go-down


32. El-Sabbagh OI, Shabaan MA, Kadry HH, Al-Din ES: Synthesis of new nonclassical acridines, quinolines, and quinazolines derived from dimedone for biological evaluation. Arch Pharm (Weinheim); 2010 Sep;343(9):519-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis of new nonclassical acridines, quinolines, and quinazolines derived from dimedone for biological evaluation.
  • [MeSH-minor] Anti-Bacterial Agents / chemical synthesis. Anti-Bacterial Agents / pharmacology. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / pharmacology. Cyclohexanones / chemistry. Cyclohexanones / pharmacology. Gram-Negative Bacteria / drug effects. Gram-Positive Bacteria / drug effects. Hep G2 Cells. Humans. Inhibitory Concentration 50. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Microbial Sensitivity Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814944.001).
  • [ISSN] 1521-4184
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acridines; 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Cyclohexanones; 0 / Quinazolines; 0 / Quinolines; B2B5DSX2FC / dimedone
  •  go-up   go-down


33. Gomes BP, Sato E, Ferraz CC, Teixeira FB, Zaia AA, Souza-Filho FJ: Evaluation of time required for recontamination of coronally sealed canals medicated with calcium hydroxide and chlorhexidine. Int Endod J; 2003 Sep;36(9):604-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After biomechanical preparation of 75 teeth, they were randomly divided into nine groups according to the intracanal medicament and the coronal seal with 'Intermediate Restorative Material' (IRM) as follows: (i) 10 teeth medicated with CG, coronally unsealed;.
  • (iv) 10 teeth medicated with CG + coronal seal;.
  • (vii) 10 teeth without intracanal medicament and coronally sealed;.
  • (viii) 5 teeth without intracanal medicament and coronally unsealed, used as the positive control group (PC);.
  • The group with no medication, but sealed with IRM, showed recontamination after 8.7 days.
  • CONCLUSION: The coronal seal delayed but did not prevent leakage of microorganisms.
  • [MeSH-major] Anti-Infective Agents, Local / therapeutic use. Calcium Hydroxide / therapeutic use. Chlorhexidine / therapeutic use. Dental Pulp Cavity / microbiology. Root Canal Irrigants / therapeutic use. Root Canal Obturation
  • [MeSH-minor] Dental Leakage / microbiology. Humans. Methylmethacrylates / therapeutic use. Root Canal Preparation. Statistics, Nonparametric. Time Factors. Zinc Oxide-Eugenol Cement / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM HYDROXIDE .
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950574.001).
  • [ISSN] 0143-2885
  • [Journal-full-title] International endodontic journal
  • [ISO-abbreviation] Int Endod J
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Methylmethacrylates; 0 / Root Canal Irrigants; 0 / Zinc Oxide-Eugenol Cement; 60318-33-4 / IRM cement; PF5DZW74VN / Calcium Hydroxide; R4KO0DY52L / Chlorhexidine
  •  go-up   go-down


34. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K: Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart; 2002 Mar;87(3):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antioxidants / administration & dosage. Biopterin / analogs & derivatives. Biopterin / pharmacology. Coronary Vessels / drug effects. Endothelium, Vascular / drug effects. Hypercholesterolemia / physiopathology
  • [MeSH-minor] Acetylcholine / pharmacology. Aged. Blood Flow Velocity / drug effects. Coronary Angiography. Coronary Circulation / drug effects. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Female. Humans. Infusions, Intra-Arterial. Laser-Doppler Flowmetry. Male. Middle Aged. Nitroglycerin / pharmacology. Vasodilator Agents / pharmacology. omega-N-Methylarginine / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Cardiol. 2000 Jan;35(1):71-5 [10636262.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 5;263(3):681-4 [10512739.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Feb;35(2):173-8 [10672847.001]
  • [Cites] J Cardiovasc Pharmacol. 2001 Mar;37(3):333-8 [11243424.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 24;131(7-8):91-4 [11416883.001]
  • [Cites] Heart. 2001 Aug;86(2):212-6 [11454846.001]
  • [Cites] Nature. 1980 Nov 27;288(5789):373-6 [6253831.001]
  • [Cites] Nature. 1987 Jun 11-17;327(6122):524-6 [3495737.001]
  • [Cites] Circulation. 1990 Feb;81(2):491-7 [2105174.001]
  • [Cites] Circulation. 1991 Feb;83(2):652-60 [1991383.001]
  • [Cites] Am J Physiol. 1991 Jun;260(6 Pt 2):H1888-92 [1905491.001]
  • [Cites] Basic Res Cardiol. 1991;86 Suppl 2:127-42 [1953605.001]
  • [Cites] Lancet. 1991 Dec 21-28;338(8782-8783):1546-50 [1683971.001]
  • [Cites] Biochem J. 1992 Jan 15;281 ( Pt 2):297-300 [1297314.001]
  • [Cites] Biochem J. 1992 Feb 1;281 ( Pt 3):627-30 [1371384.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):29-37 [8423226.001]
  • [Cites] Am J Physiol. 1993 Mar;264(3 Pt 2):H722-7 [8456975.001]
  • [Cites] J Clin Invest. 1993 Aug;92(2):652-62 [8349804.001]
  • [Cites] Annu Rev Nutr. 1993;13:261-86 [8103664.001]
  • [Cites] Circulation. 1994 Jun;89(6):2525-32 [8205660.001]
  • [Cites] Circulation. 1995 Jan 1;91(1):139-44 [7528647.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11462-7 [8626704.001]
  • [Cites] Am Heart J. 1996 Jun;131(6):1051-7 [8644581.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):41-6 [9011574.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 18;237(2):340-4 [9268712.001]
  • [Cites] Am J Cardiol. 1997 Sep 15;80(6):751-5 [9315582.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2309-15 [9409197.001]
  • [Cites] Heart. 1997 Nov;78(5):493-8 [9415011.001]
  • [Cites] Circulation. 1998 Nov 3;98(18):1842-7 [9799202.001]
  • [Cites] Circulation. 1999 Jan 19;99(2):224-9 [9892587.001]
  • [Cites] Circ Res. 2000 Feb 4;86(2):E36-41 [10666424.001]
  • (PMID = 11847169.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Enzyme Inhibitors; 0 / Vasodilator Agents; 22150-76-1 / Biopterin; 27JT06E6GR / omega-N-Methylarginine; EGX657432I / sapropterin; G59M7S0WS3 / Nitroglycerin; N9YNS0M02X / Acetylcholine
  • [Other-IDs] NLM/ PMC1767023
  •  go-up   go-down


35. Trygstad TK, Hansen RA, Wegner SE: Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability. J Manag Care Pharm; 2006 Mar;12(2):108-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
  • OBJECTIVE: The conversion of loratadine from prescription (Rx)-only to over-the-counter (OTC) status on November 27, 2002, brought about the question of how OTC products may influence utilization of both OTC and Rx-only low-sedating antihistamines (LSAs) simultaneously.
  • The objective of this study was to determine patterns of LSA utilization in relation to changes in OTC availability and Medicaid coverage policy and to assess the rate of product switching associated with these policies.
  • METHODS: Administrative pharmacy claims from the NC Medicaid population of approximately 1.1 million eligible recipients were used to study the 3 years of LSA use between July 1, 2001, and June 30, 2004.
  • Two general methods were employed to evaluate the extent of product switching.
  • First, monthly rates of incident use, new starts (i.e., no LSA use in the prior 12-month period) and product switching in time series were determined.
  • Second, product switching was assessed through the use of rate-ratio calculations.
  • RESULTS: The use of individual drugs within the LSA class responded to coverage changes as expected, with alternative LSAs replacing loratadine use in the loratadine noncoverage period.
  • Switching behavior for individual drugs within the LSA class was strongly associated with coverage changes.
  • Recipients using loratadine were 2.16 times more likely to switch to an alternative Rx-only antihistamine in the noncoverage period (95% confidence interval [CI], 2.10-2.22) as compared with the baseline period.
  • CONCLUSION: Medicaid recipients switched to another covered (Rx) LSA when loratadine became available as an OTC and was not covered.
  • Although coverage of loratadine OTC offers a substantial cost-savings opportunity for the Medicaid program compared with Rx-only LSAs, not covering the OTC product immediately at the time of OTC availability contributed to (a) increased switching to Rx-only LSA products and (b) little use of loratadine OTC in the subsequent OTC coverage period.
  • [MeSH-major] Histamine H1 Antagonists, Non-Sedating / administration & dosage. Insurance, Pharmaceutical Services. Loratadine / administration & dosage. Medicaid / organization & administration. Nonprescription Drugs
  • [MeSH-minor] Cetirizine / administration & dosage. Drug Utilization Review. Humans. Insurance Claim Review. North Carolina. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Medicaid.
  • MedlinePlus Health Information. consumer health - Over-the-Counter Medicines.
  • Hazardous Substances Data Bank. LORATADINE .
  • Hazardous Substances Data Bank. Cetirizine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515369.001).
  • [ISSN] 1083-4087
  • [Journal-full-title] Journal of managed care pharmacy : JMCP
  • [ISO-abbreviation] J Manag Care Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H1 Antagonists, Non-Sedating; 0 / Nonprescription Drugs; 7AJO3BO7QN / Loratadine; FVF865388R / desloratadine; YO7261ME24 / Cetirizine
  •  go-up   go-down


36. Takayama T, Nomura Y: [A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer]. Gan To Kagaku Ryoho; 2000 Jan;27(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Double-Blind Method. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Middle Aged. Proportional Hazards Models

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10660736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CF protocol
  •  go-up   go-down


37. Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, Wang H: Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol; 2008 Mar;35(3):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1. The aim of the present study was to investigate the effect and mechanism of berberine, an alkaloid extracted from the traditional Chinese medicine coptis, on rat liver fibrosis induced by multiple hepatotoxic factors.
  • [MeSH-major] Berberine / therapeutic use. Drug-Induced Liver Injury / drug therapy. Liver Cirrhosis / chemically induced. Liver Cirrhosis / drug therapy
  • [MeSH-minor] Actins / metabolism. Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Carbon Tetrachloride / adverse effects. Cholesterol / adverse effects. Dose-Response Relationship, Drug. Ethanol / adverse effects. Hydroxyproline / metabolism. Liver / metabolism. Liver / pathology. Male. Malondialdehyde / metabolism. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. CARBON TETRACHLORIDE .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973934.001).
  • [ISSN] 1440-1681
  • [Journal-full-title] Clinical and experimental pharmacology & physiology
  • [ISO-abbreviation] Clin. Exp. Pharmacol. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Actins; 0 / smooth muscle actin, rat; 0I8Y3P32UF / Berberine; 3K9958V90M / Ethanol; 4Y8F71G49Q / Malondialdehyde; 97C5T2UQ7J / Cholesterol; CL2T97X0V0 / Carbon Tetrachloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; RMB44WO89X / Hydroxyproline
  •  go-up   go-down


38. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K, Nicolle L, Karpinski M, Jeffery J, Nickerson P: Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol; 2004 Jan;15(1):219-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic-based detection of urine proteins associated with acute renal allograft rejection.
  • This study sought to determine whether such candidate proteins can be detected in urine using mass spectrometry.
  • Four patient groups were rigidly defined on the basis of allograft function, clinical course, and allograft biopsy result: acute clinical rejection group (n = 18), stable transplant group (n = 22), acute tubular necrosis group (n = 5), and recurrent (or de novo) glomerulopathy group (n = 5).
  • In conclusion, proteomic technology together with stringent definition of patient groups can detect urine proteins associated with acute renal allograft rejection.
  • Identification of these proteins may prove useful as non-invasive diagnostic markers for rejection and the development of novel therapeutic agents.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14694176.001).
  • [ISSN] 1046-6673
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Hwang SY, Kim WJ, Wee JJ, Choi JS, Kim SK: Panax ginseng improves survival and sperm quality in guinea pigs exposed to 2,3,7,8-tetrachlorodibenzo- p-dioxin. BJU Int; 2004 Sep;94(4):663-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All TT animals died within 18 days after TCDD exposure, but 40-70% of the PG-WE-treated groups, depending on the group, survived until death at 40 weeks.
  • G Group animals had higher sperm quality than that of NCs even long after discontinuing PG-WE.
  • [MeSH-major] Environmental Pollutants / toxicity. Panax. Paternal Exposure / adverse effects. Plant Extracts / pharmacology. Spermatozoa / drug effects. Tetrachlorodibenzodioxin / analogs & derivatives. Tetrachlorodibenzodioxin / toxicity
  • [MeSH-minor] Animals. Cell Survival / drug effects. Female. Guinea Pigs. Male. Pregnancy. Pregnancy Rate. Pregnancy, Animal. Sperm Motility / drug effects

  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15329132.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Plant Extracts; 84245-14-7 / tetrachlorofluorodibenzo-4-dioxin; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


40. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg; 2001 Apr;121(4):714-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arteriosclerosis / therapy. Carotid Artery Diseases / prevention & control. Carotid Artery, Common / surgery. Carrier Proteins. Cell Cycle Proteins / therapeutic use. DNA-Binding Proteins. Genetic Therapy / methods. Jugular Veins / transplantation. Transcription Factors / therapeutic use
  • [MeSH-minor] Anastomosis, Surgical. Animals. Antimetabolites / pharmacokinetics. Antimetabolites / therapeutic use. Bromodeoxyuridine / pharmacokinetics. Bromodeoxyuridine / therapeutic use. Cell Division / drug effects. Cholesterol, Dietary / toxicity. DNA Probes / chemistry. Disease Progression. E2F Transcription Factors. Hypertrophy. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / pathology. Proliferating Cell Nuclear Antigen / drug effects. Proliferating Cell Nuclear Antigen / metabolism. Rabbits. Retinoblastoma-Binding Protein 1. Transcription Factor DP1. Transfection. Tunica Intima / drug effects. Tunica Intima / pathology. Up-Regulation / drug effects

  • MedlinePlus Health Information. consumer health - Carotid Artery Disease.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11279413.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL35610; United States / NHLBI NIH HHS / HL / HL58516; United States / NHLBI NIH HHS / HL / HL59316; United States / NHLBI NIH HHS / HL / HL61661
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / Cholesterol, Dietary; 0 / DNA Probes; 0 / DNA-Binding Proteins; 0 / E2F Transcription Factors; 0 / Proliferating Cell Nuclear Antigen; 0 / Retinoblastoma-Binding Protein 1; 0 / Transcription Factor DP1; 0 / Transcription Factors; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


41. López IC, Bermejo PG, Espiga PJ, Tapia DQ: [L-dopa sensitive Parkinsonism in neurocysticercosis]. Neurologia; 2008 Mar;23(2):119-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We present the case of a 29-year old woman with serologically confirmed NC and obstructive hydrocephalia secondary to a cyst in the IV ventricle.
  • She developed Parkinsonian's syndrome, which subsided after combined treatment with cysticidal drugs and L-dopa.
  • [MeSH-major] Levodopa / therapeutic use. Neurocysticercosis / complications. Parkinsonian Disorders

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322832.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anthelmintics; 46627O600J / Levodopa
  •  go-up   go-down


42. Andersson JO, Andersson SG: Pseudogenes, junk DNA, and the dynamics of Rickettsia genomes. Mol Biol Evol; 2001 May;18(5):829-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The typhus-causing agent, Rickettsia prowazekii, is exceptional in that as much as 24% of its 1.1-Mb genome consists of noncoding DNA and pseudogenes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11319266.001).
  • [ISSN] 0737-4038
  • [Journal-full-title] Molecular biology and evolution
  • [ISO-abbreviation] Mol. Biol. Evol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AJ293310/ AJ293311/ AJ293312/ AJ293313/ AJ293314/ AJ293315/ AJ293316/ AJ293317/ AJ293318/ AJ293319/ AJ293320/ AJ293321/ AJ293322/ AJ293323/ AJ293324/ AJ293325/ AJ293326/ AJ293327/ AJ293328/ AJ293329/ AJ293330
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 12133JR80S / Guanosine; 8J337D1HZY / Cytosine
  •  go-up   go-down


43. Roldan A, Warren OU, Russell RS, Liang C, Wainberg MA: A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription. J Biol Chem; 2005 Apr 29;280(17):17488-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Yet, surprisingly, multimerization of Gag-related proteins did not abrogate this annealing process but rather resulted in dramatically reduced levels of reverse transcriptase processivity.
  • [MeSH-major] Gene Products, gag / chemistry. Gene Products, gag / physiology. HIV-1 / metabolism. Nucleocapsid / chemistry. Protein Precursors / chemistry. Protein Precursors / physiology. RNA, Transfer, Amino Acyl / chemistry. Transcription, Genetic
  • [MeSH-minor] DNA / chemistry. DNA Primers / chemistry. Dimerization. Dose-Response Relationship, Drug. Hot Temperature. In Vitro Techniques. Models, Biological. Models, Genetic. Mutation. Nucleic Acid Conformation. Polymerase Chain Reaction. Protein Binding. Protein Folding. Protein Structure, Tertiary. Proteins / chemistry. RNA / chemistry. RNA, Transfer / chemistry

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731102.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Gene Products, gag; 0 / Protein Precursors; 0 / Proteins; 0 / RNA, Transfer, Amino Acyl; 0 / p55 gag precursor protein, Human immunodeficiency virus 1; 63231-63-0 / RNA; 9007-49-2 / DNA; 9014-25-9 / RNA, Transfer
  •  go-up   go-down


44. Sall A, Liu Z, Zhang HM, Yuan J, Lim T, Su Y, Yang D: MicroRNAs-based therapeutic strategy for virally induced diseases. Curr Drug Discov Technol; 2008 Mar;5(1):49-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the present, although the biological functions of miRNAs are not completely revealed, a growing body of evidence implicates that miRNA pathway is a new mechanism of gene regulation in both normal and diseased conditions and therefore investigation of miRNA biogenesis and function may add new tools for gene functional study and drug development.
  • In this article, we will briefly review the structure, biogenesis and basic mechanism of action of miRNAs identified in higher organisms and viruses and then focus on the recent progress in research for drug development using the miRNA pathway as a strategy.
  • Particularly, we will discuss the advance, challenge and future directions on antiviral drug development using miRNA as a target or a gene silencing tool for the treatment of viral infections.
  • [MeSH-major] MicroRNAs / therapeutic use. Virus Diseases / drug therapy
  • [MeSH-minor] Animals. Gene Silencing / drug effects. Humans. Oligonucleotides / therapeutic use. RNA, Viral / genetics. Viruses / genetics

  • MedlinePlus Health Information. consumer health - Viral Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537567.001).
  • [ISSN] 1570-1638
  • [Journal-full-title] Current drug discovery technologies
  • [ISO-abbreviation] Curr Drug Discov Technol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Oligonucleotides; 0 / RNA, Viral
  • [Number-of-references] 117
  •  go-up   go-down


45. Kuehbacher A, Urbich C, Dimmeler S: Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci; 2008 Jan;29(1):12-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Drug Delivery Systems. Gene Expression Regulation / drug effects. MicroRNAs / drug effects
  • [MeSH-minor] Cardiovascular Diseases / drug therapy. Cardiovascular Diseases / physiopathology. Humans. Neoplasms / drug therapy. Neoplasms / physiopathology. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / physiopathology. Neovascularization, Physiologic / physiology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068232.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


46. Peng SM, Wang SZ, Zhao JP: [Effect of rhubarb on inflammatory cytokines and complements in patients with systemic inflammation reaction syndrome and its significance]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Apr;22(4):264-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of rhubarb on inflammatory cytokines and complements in patients with systemic inflammation reaction syndrome and its significance].
  • OBJECTIVE: To study the effect of rhubarb in treating patients with systemic inflammation reaction syndrome (SIRS) and its mechanism.
  • METHODS: The 40 patients with SIRS in the treated group were treated with conventional treatment plus rhubarb powder orally or by nasal feeding, the 38 patients in the control group were treated with conventional treatment alone.
  • Serum tumor necrosis factor-alpha (TNF-alpha) was determined by ELISA during the admission and the 3rd day after admission, C-reactive protein (C-RP), complement 3 and 4 (C3, C4) were also determined by auto-scattering turbidimetric quantitative analysis.
  • The parameters were compared between groups and with normal control group.
  • RESULTS: Cure rate in the treated group was significantly higher than that in the control group accompanied with lesser occurrence of multiple organ dysfunction syndrome (MODS) and lower mortality.
  • Serum TNF-alpha, C-RP, C3 and C4 in the SIRS patients were increased during admission, which were significantly higher than normal control, but these parameters would be reduced together with the alleviating of symptoms after treatment, particularly after rhubarb treatment.
  • CONCLUSION: Rhubarb could improve the prognosis of patients with SIRS, its major mechanism is that rhubarb has the antagonizing effect against inflammatory cytokines and complements.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12584786.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Complement C3; 0 / Complement C4; 0 / Cytokines; 0 / Drugs, Chinese Herbal; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


47. Pan YJ, Li XY, Yang GT: [Effect of tanshinone II A on the calcineurin activity in proliferating vascular smooth muscle cells of rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Feb;29(2):133-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of tanshinone II A on the calcineurin activity in proliferating vascular smooth muscle cells of rats].
  • OBJECTIVE: To study the effect of tanshinone II A (TSN) on angiotensin II (Ang II) induced proliferation of vascular smooth muscle cells (VSMCs).
  • METHODS: VSMCs were cultured by explant attached method, and induced to proliferative cell model with Ang II.
  • The effect of TSN in different concentrations on calcineurin (CaN) activity was detected by enzyme reaction phosphorus measurement; the CaN mRNA expression was detected by RT-PCR; and the expression of proliferating cell nuclear antigen (PCNA) were observed by immunocytochemical method.
  • RESULTS: Compared with the normal control group, Ang II could significantly stimulate the proliferation of VSMCs, showing obviously elevated degree of proliferation activity (P <0. 01).
  • After being treated with TSN, all the indexes, including CaN activity, CaN mRNA expression and PCNA expression, were obviously reduced in a dose-dependent manner (P<0.05, P<0.01).
  • CONCLUSION: VSMCs proliferation can be inhibited by TSN in a dose-dependent manner and the inhibiting mechanism may be related to the down-regulation of CaN activities and the inhibition on CaN mRNA and PCNA expressions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382473.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Diterpenes, Abietane; 0 / Phenanthrenes; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; 03UUH3J385 / tanshinone; 11128-99-7 / Angiotensin II; EC 3.1.3.16 / Calcineurin
  •  go-up   go-down


48. Zhao LJ, Liu N, Li XP, Wang JL, Wei LH: Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells. Chin Med J (Engl); 2010 May 5;123(9):1170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Type I gonadotropin-releasing hormone (GnRH-I) agonists have been applied for the treatment of steroid-dependent tumors such as breast carcinoma, ovarian cancer and prostatic carcinoma.
  • Type II GnRH (GnRH-II) is a new subtype of GnRH.
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. RNA Interference. Triptorelin Pamoate / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20529558.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


49. Noda T, Ebihara H, Muramoto Y, Fujii K, Takada A, Sagara H, Kim JH, Kida H, Feldmann H, Kawaoka Y: Assembly and budding of Ebolavirus. PLoS Pathog; 2006 Sep;2(9):e99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further our understanding of the Ebolavirus life cycle, we expressed the various viral proteins in mammalian cells and examined them ultrastructurally and biochemically.
  • These data form a foundation for the identification and development of potential antiviral agents to combat the devastating disease caused by this virus.

  • MedlinePlus Health Information. consumer health - Ebola.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 Jun;75(11):5205-14 [11333902.001]
  • [Cites] Virology. 2000 Apr 10;269(2):325-34 [10753711.001]
  • [Cites] J Virol. 2002 Mar;76(5):2518-28 [11836430.001]
  • [Cites] J Gen Virol. 2002 Mar;83(Pt 3):611-21 [11842256.001]
  • [Cites] J Exp Med. 2002 Mar 4;195(5):593-602 [11877482.001]
  • [Cites] J Virol. 2002 May;76(10):4855-65 [11967302.001]
  • [Cites] Mol Cell. 2002 Aug;10(2):307-16 [12191476.001]
  • [Cites] Virology. 2002 Sep 30;301(2):212-25 [12359424.001]
  • [Cites] J Virol. 2003 Feb;77(3):1812-9 [12525615.001]
  • [Cites] J Mol Biol. 2003 Feb 14;326(2):493-502 [12559917.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):677-85 [12974482.001]
  • [Cites] J Virol. 2004 Jan;78(2):999-1005 [14694131.001]
  • [Cites] J Virol. 2004 Jul;78(14):7344-51 [15220407.001]
  • [Cites] Curr Top Microbiol Immunol. 2004;283:145-96 [15298170.001]
  • [Cites] J Cell Biol. 1981 Jun;89(3):700-5 [6265471.001]
  • [Cites] Gene. 1991 Dec 15;108(2):193-9 [1660837.001]
  • [Cites] Virus Res. 1995 Dec;39(2-3):129-50 [8837880.001]
  • [Cites] J Virol. 1997 Sep;71(9):6706-13 [9261394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5746-51 [9576955.001]
  • [Cites] Virology. 1998 Sep 30;249(2):406-17 [9791031.001]
  • [Cites] J Virol. 1999 Mar;73(3):2333-42 [9971816.001]
  • [Cites] J Virol. 2005 Apr;79(8):4709-19 [15795257.001]
  • [Cites] J Vet Med Sci. 2005 Mar;67(3):325-8 [15805739.001]
  • [Cites] J Virol Methods. 2005 Jul;127(1):1-9 [15893559.001]
  • [Cites] Virol J. 2005;2:92 [16367999.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6 [11095724.001]
  • [Cites] Virology. 2000 Dec 5;278(1):20-6 [11112476.001]
  • [Cites] Virology. 2001 Apr 25;283(1):1-6 [11312656.001]
  • [Cites] Nat Med. 2001 Dec;7(12):1313-9 [11726971.001]
  • (PMID = 17009868.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI057153; United States / NIAID NIH HHS / AI / 1-U54-AI-057153
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleocapsid Proteins; 0 / VP40 protein, virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC1579243
  •  go-up   go-down


50. Raja C, Ferner J, Dietrich U, Avilov S, Ficheux D, Darlix JL, de Rocquigny H, Schwalbe H, Mély Y: A tryptophan-rich hexapeptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein. Biochemistry; 2006 Aug 1;45(30):9254-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tryptophan-rich hexapeptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein.
  • Since the recognition of target nucleic acids is required in the initial step of most NC-mediated processes, attempts were made to find small molecules capable of competing with this recognition.
  • To further validate these peptides as potential anti-NC agents, we studied the ability of Ac-HKWPWW-NH2, taken as a representative, to interfere with the NC chaperone properties required during reverse transcription.
  • [MeSH-major] HIV-1 / metabolism. Molecular Chaperones / metabolism. Nucleocapsid Proteins / metabolism. Oligopeptides / metabolism. RNA-Binding Proteins / metabolism. Tryptophan / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Humans. Magnetic Resonance Spectroscopy. Molecular Sequence Data. Nucleic Acids / chemistry. Nucleic Acids / metabolism. Protein Binding. Protein Conformation. Protein Structure, Secondary. Spectrometry, Fluorescence

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866372.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Chaperones; 0 / Nucleic Acids; 0 / Nucleocapsid Proteins; 0 / Oligopeptides; 0 / RNA-Binding Proteins; 136628-24-5 / trans-activation responsive RNA-binding protein; 8DUH1N11BX / Tryptophan
  •  go-up   go-down


51. Yun MY, Yang JH, Kim DK, Cheong KJ, Song HH, Kim DH, Cheong KJ, Kim YI, Shin SC: Therapeutic effects of Baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by dermatophagoides pteronyssinus. Int Immunopharmacol; 2010 Sep;10(9):1142-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was conducted to investigate the effects of Baicalein (BE), which is hydrolyzed product of Baicalin (BA), on atopic dermatitis (AD).
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Dermatitis, Atopic / drug therapy. Dermatophagoides pteronyssinus / immunology. Flavanones / therapeutic use
  • [MeSH-minor] Animals. Antigens, CD / analysis. Antigens, CD / immunology. Antigens, CD11 / analysis. Antigens, CD11 / immunology. Antigens, CD3 / analysis. Antigens, CD3 / immunology. Antigens, CD45 / analysis. Antigens, CD45 / immunology. Antigens, Differentiation, T-Lymphocyte / analysis. Antigens, Differentiation, T-Lymphocyte / immunology. Cells, Cultured. Female. Immunoglobulin E / analysis. Immunoglobulin E / immunology. Inflammation / immunology. Inflammation / pathology. Inflammation Mediators / analysis. Inflammation Mediators / immunology. Interferon-gamma / immunology. Interleukin-6 / blood. Interleukin-6 / immunology. Lectins, C-Type / analysis. Lectins, C-Type / immunology. Mice. Receptors, CCR3 / analysis. Receptors, CCR3 / immunology. Severity of Illness Index. Skin / drug effects. Skin / immunology. Skin / pathology. Spleen / drug effects. Spleen / immunology. Tumor Necrosis Factor-alpha / blood. Tumor Necrosis Factor-alpha / immunology. Up-Regulation / drug effects. Up-Regulation / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20621172.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antigens, CD; 0 / Antigens, CD11; 0 / Antigens, CD3; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / CD69 antigen; 0 / Ccr3 protein, mouse; 0 / Flavanones; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Lectins, C-Type; 0 / Receptors, CCR3; 0 / Tumor Necrosis Factor-alpha; 37341-29-0 / Immunoglobulin E; 49QAH60606 / baicalein; 82115-62-6 / Interferon-gamma; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


52. Wang Y, Shen LH, Chen WJ, Liu M, Li F, Liao ZG: [Expressions of Bcl-2 and Caspase-3 in the internal organs of rats when tetramine was administered]. Fa Yi Xue Za Zhi; 2006 Aug 15;22(4):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bridged Compounds / poisoning. Caspase 3 / metabolism. Liver / metabolism. Myocardium / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Immunohistochemistry. Kidney / metabolism. Kidney / pathology. Lung / metabolism. Lung / pathology. Male. Random Allocation. Rats. Rats, Sprague-Dawley. Spleen / metabolism. Spleen / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080656.001).
  • [ISSN] 1004-5619
  • [Journal-full-title] Fa yi xue za zhi
  • [ISO-abbreviation] Fa Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; F6TS3WME05 / tetramethylenedisulfotetramine
  •  go-up   go-down


53. Yang Q, Zhang YS: [Effects of Qichu Fujin Recipe on regeneration and repair of injured sciatic nerve in rats]. Zhong Xi Yi Jie He Xue Bao; 2009 Sep;7(9):848-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the effects of Qichu Fujin Recipe (QCFJR), a compound traditional Chinese medicine, in repairing sciatic nerve injury in rats.
  • [MeSH-major] Drugs, Chinese Herbal / pharmacology. Nerve Regeneration / drug effects. Sciatic Nerve / injuries
  • [MeSH-minor] Animals. Male. Rats. Rats, Sprague-Dawley. Sciatic Neuropathy / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747441.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


54. Saulnier A, Pelletier I, Labadie K, Colbère-Garapin F: Complete cure of persistent virus infections by antiviral siRNAs. Mol Ther; 2006 Jan;13(1):142-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small interfering RNAs (siRNAs) have been developed as antiviral agents for mammalian cells.
  • The capacity of specific siRNAs to prevent virus infections has been demonstrated, and there is evidence that these new antiviral agents could have a partial therapeutic effect a few days after infection.
  • [MeSH-minor] Animals. Cell Line. Cercopithecus aethiops. Humans. Mutation. Poliomyelitis / therapy. RNA Interference. RNA, Viral / analysis. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157509.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / RNA, Viral
  •  go-up   go-down


55. Grodzińska L, Starzyk D, Bieroń K, Goszcz A, Korbut R: Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study. Basic Clin Pharmacol Toxicol; 2005 Jun;96(6):413-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, we designed a pilot study in 10 normocholesterolaemic and 10 hypercholesterolaemic patients with peripheral arterial occlusive disease to investigate potential biological effects of statins in relation to their effects on endothelial function.
  • Euglobulin clot lysis time was shortened significantly in both groups each time after drug intake.
  • Simvastatin inhibited platelet aggregation induced by collagen and ADP in both study groups 3 hr after intake, but the platelets of hypercholesterolaemic patients were less sensitive to these aggregatory agents after 3 months of treatment.
  • [MeSH-major] Anticholesteremic Agents / therapeutic use. Arterial Occlusive Diseases / drug therapy. Hypercholesterolemia / drug therapy. Simvastatin / therapeutic use
  • [MeSH-minor] Aged. Ankle / blood supply. Blood Coagulation Tests. Blood Pressure / drug effects. Blood Pressure / physiology. Blood Pressure Determination. Brachial Artery / physiology. Cholesterol / blood. Cholesterol, HDL / blood. Cholesterol, LDL / blood. Exercise Test / drug effects. Female. Humans. Male. Middle Aged. Platelet Aggregation / drug effects. Serum Globulins / drug effects. Serum Globulins / physiology. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910404.001).
  • [ISSN] 1742-7835
  • [Journal-full-title] Basic & clinical pharmacology & toxicology
  • [ISO-abbreviation] Basic Clin. Pharmacol. Toxicol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Serum Globulins; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; AGG2FN16EV / Simvastatin
  •  go-up   go-down


56. Shin ES, Garcia-Garcia HM, Serruys PW: A new method to measure necrotic core and calcium content in coronary plaques using intravascular ultrasound radiofrequency-based analysis. Int J Cardiovasc Imaging; 2010 Apr;26(4):387-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method to measure necrotic core and calcium content in coronary plaques using intravascular ultrasound radiofrequency-based analysis.
  • Although previous intravascular ultrasound (IVUS) radiofrequency-based analysis data showed acceptable reproducibility for plaque composition, measurements are not easily obtained, particularly that of lumen contour, because of the limited IVUS resolution.
  • The purpose of this study was to compare a new measurement method (Shin's method) and the conventional measurement method for necrotic core and calcium content in atherosclerotic lesions using Virtual Histology-intravascular ultrasound (VH-IVUS).
  • Fifty-seven patients with unstable angina who underwent elective percutaneous coronary intervention were included.
  • Shin's method focuses on catheter contour, instead of lumen contour, and vessel contour.
  • Patients ages ranged from 46 to 88 years, and 34 were men.
  • A total of 1,401 frames from 59 culprit lesions were assessed.
  • There were no significant differences in the mean area and volume of necrotic core and dense calcium between the two methods.
  • Correlation coefficients (R) were >or=0.99 for all above mentioned parameters (P < 0.001).
  • Between methods, the absolute differences in mean area and volume of necrotic core were 0.02 +/- 0.02 mm(2) and 0.34 +/- 0.29 mm(3), respectively, while for mean area and volume of dense calcium, the absolute differences were 0.04 +/- 0.07 mm(2) and 0.36 +/- 0.52 mm(3), respectively.
  • The reproducibility of Shin's method was excellent.
  • For area of the necrotic core and dense calcium, the means of the differences between the two measurements were nearly zero, and the reproducibility coefficients were within 1% of the means of the two measurements.
  • Mean analysis time for both measurements was 26.8 +/- 6.7 min/segment in the conventional method and 3.3 +/- 0.6 min/segment in Shin's method.
  • Shin's method for measurement of necrotic core and dense calcium using VH-IVUS demonstrated a good correlation with the conventional method and excellent reproducibility.
  • Also, Shin's method required a significantly shorter analysis time than the conventional method.
  • Therefore, Shin's method could replace the conventional method for necrotic core and calcium measurement in atherosclerotic lesions, and it might be useful in the catheterization laboratory for online clinical decision.
  • [MeSH-major] Calcinosis / ultrasonography. Coronary Artery Disease / ultrasonography. Coronary Vessels / ultrasonography. Image Interpretation, Computer-Assisted. Ultrasonography, Interventional / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Angina, Unstable / etiology. Angina, Unstable / ultrasonography. Angioplasty, Balloon, Coronary. Female. Humans. Male. Middle Aged. Necrosis. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2002 Oct 1;106(14):1893-900 [12356647.001]
  • [Cites] J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C13-8 [16631505.001]
  • [Cites] Curr Drug Targets Cardiovasc Haematol Disord. 2003 Sep;3(3):218-26 [12871040.001]
  • [Cites] Herz. 2003 Sep;28(6):488-95 [14569389.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Am Heart Hosp J. 2003 Spring;1(2):164-9 [15815137.001]
  • [Cites] J Am Coll Cardiol. 2005 Jun 21;45(12):1946-53 [15963391.001]
  • [Cites] Am J Cardiol. 2005 Dec 1;96(11):1476-83 [16310425.001]
  • [Cites] Eur Heart J. 2006 Mar;27(6):655-63 [16415094.001]
  • [Cites] J Am Coll Cardiol. 2006 Mar 21;47(6):1134-42 [16545642.001]
  • [Cites] J Am Coll Cardiol. 2006 Jun 20;47(12):2405-12 [16781367.001]
  • [Cites] Eur Heart J. 2006 Aug;27(16):1921-7 [16840496.001]
  • [Cites] Eur Heart J. 2007 Jun;28(11):1283-8 [17483541.001]
  • [Cites] Eur Heart J. 2007 Jul;28(14):1783-4 [17488759.001]
  • [Cites] Heart. 2007 Aug;93(8):977-82 [17502324.001]
  • [Cites] Am J Cardiol. 2007 Sep 15;100(6):953-9 [17826376.001]
  • [Cites] Am J Cardiol. 2008 Apr 15;101(8):1079-83 [18394436.001]
  • [Cites] Circulation. 2008 Sep 9;118(11):1172-82 [18765397.001]
  • [Cites] Heart. 2009 Aug;95(16):1362-74 [19638515.001]
  • [Cites] Circ J. 2009 Sep;73(9):1557-60 [19638706.001]
  • [Cites] Circulation. 2002 Oct 22;106(17):2200-6 [12390948.001]
  • (PMID = 20063068.001).
  • [ISSN] 1875-8312
  • [Journal-full-title] The international journal of cardiovascular imaging
  • [ISO-abbreviation] Int J Cardiovasc Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2852593
  •  go-up   go-down


57. Janowski BA, Corey DR: Minireview: Switching on progesterone receptor expression with duplex RNA. Mol Endocrinol; 2010 Dec;24(12):2243-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minireview: Switching on progesterone receptor expression with duplex RNA.
  • It has long been appreciated that gene expression is regulated by protein complexes at promoters.
  • More recently, research has demonstrated that small duplex RNAs such as micro-RNAs and short interfering RNAs complementary to mRNA provide another layer of regulation.
  • Evidence now supports the existence of regulatory pathways that use small duplex RNAs to control transcription.
  • Synthetic RNAs complementary to gene promoters [antigene RNAs (agRNAs)] can either activate or inhibit gene expression.
  • Activity of agRNAs is mediated by argonaute, a protein required for RNA interference.
  • Unlike protein transcription factors, agRNAs do not bind to chromosomal DNA but recognize noncoding transcripts that overlap gene promoters or 3'-gene termini.
  • This review describes recent studies with agRNAs and focuses on the robust and potent agRNA-mediated regulation of progesterone receptor.
  • The ability of small RNAs to alter transcription provides a new layer of potential regulation for gene expression.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Plant Biol. 2007 Oct;10(5):512-9 [17702644.001]
  • [Cites] Mol Cell. 2008 Jan 18;29(1):1-7 [18206964.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13 [18227514.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):698-703 [18347154.001]
  • [Cites] IUBMB Life. 2008 Mar;60(3):159-64 [18380007.001]
  • [Cites] Mol Endocrinol. 2010 May;24(5):1090-105 [20219889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5160-5 [18375767.001]
  • [Cites] Dev Biol. 2008 Jul 15;319(2):416-25 [18501343.001]
  • [Cites] Nat Struct Mol Biol. 2008 Aug;15(8):842-8 [18604220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16230-5 [18852463.001]
  • [Cites] PLoS Genet. 2008 Nov;4(11):e1000258 [19008947.001]
  • [Cites] Biochim Biophys Acta. 2009 Jan;1789(1):3-16 [18789407.001]
  • [Cites] Science. 2008 Dec 19;322(5909):1855-7 [19056939.001]
  • [Cites] PLoS Biol. 2008 Dec 2;6(12):2911-27 [19053175.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Feb;10(2):141-8 [19145236.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Cell. 2009 Feb 20;136(4):642-55 [19239886.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1719-34 [19188450.001]
  • [Cites] Nucleic Acids Res. 2009 May;37(9):2984-95 [19304753.001]
  • [Cites] EMBO J. 2009 Jun 17;28(12):1708-19 [19461583.001]
  • [Cites] Nat Struct Mol Biol. 2009 Jul;16(7):717-24 [19543290.001]
  • [Cites] Bioorg Med Chem Lett. 2009 Jul 15;19(14):3791-4 [19423343.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2343-6 [19571673.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Sep;10(9):637-43 [19638999.001]
  • [Cites] Mol Cell. 2009 Oct 23;36(2):178-91 [19854129.001]
  • [Cites] Nucleic Acids Res. 2010 Jan;38(Database issue):D98-104 [19910371.001]
  • [Cites] Nat Rev Drug Discov. 2010 Jan;9(1):57-67 [20043028.001]
  • [Cites] Nucleic Acids Res. 2010 Jan;38(1):1-16 [19843612.001]
  • [Cites] Sci Signal. 2010;3(107):ra8 [20124551.001]
  • [Cites] J Endocrinol. 2000 May;165(2):371-8 [10810301.001]
  • [Cites] Recent Prog Horm Res. 2002;57:339-55 [12017551.001]
  • [Cites] Front Biosci. 2002 Sep 1;7:d1879-98 [12161340.001]
  • [Cites] Cell. 2006 Mar 10;124(5):957-71 [16530043.001]
  • [Cites] Drug Discov Today. 2006 Jun;11(11-12):503-8 [16713901.001]
  • [Cites] Mol Cell. 2006 Jun 9;22(5):657-68 [16762838.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1833-7 [12193640.001]
  • [Cites] Nucleic Acids Res. 2002 Oct 1;30(19):4118-26 [12364590.001]
  • [Cites] Science. 2004 Jan 30;303(5658):669-72 [14752161.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):185-97 [15260970.001]
  • [Cites] J Biol Chem. 2004 Sep 3;279(36):37982-96 [15234981.001]
  • [Cites] Science. 2004 Aug 27;305(5688):1289-92 [15297624.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1437-41 [15284456.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):211-7 [15311210.001]
  • [Cites] Endocrinology. 1988 Mar;122(3):935-44 [3342760.001]
  • [Cites] EMBO J. 1990 May;9(5):1603-14 [2328727.001]
  • [Cites] Endocrinology. 1994 Feb;134(2):658-64 [7507831.001]
  • [Cites] Cell. 1994 Feb 11;76(3):567-76 [8313476.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2476-81 [8637899.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):143-51 [9923855.001]
  • [Cites] Cell. 1999 Apr 2;97(1):17-27 [10199399.001]
  • [Cites] Mol Endocrinol. 1999 Jun;13(6):829-36 [10379882.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):906-10 [16025112.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1559-63 [16141072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):16967-72 [16284254.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):210-5 [16408037.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):216-22 [16408038.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1176 [16810259.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):793-7 [16936726.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):787-92 [16936728.001]
  • [Cites] Biol Reprod. 2006 Nov;75(5):697-704 [16855208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42 [17085592.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):871-8 [17121828.001]
  • [Cites] Nat Chem Biol. 2007 Mar;3(3):166-73 [17259978.001]
  • [Cites] Nature. 2007 May 24;447(7143):399-406 [17522672.001]
  • [Cites] Science. 2007 Jun 8;316(5830):1484-8 [17510325.001]
  • [Cites] Genome Res. 2007 Jun;17(6):682-90 [17567989.001]
  • [Cites] Genes Dev. 2007 Jun 15;21(12):1530-45 [17575054.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6637-46 [17638874.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12422-7 [17640892.001]
  • [Cites] Nucl Recept Signal. 2007;5:e006 [17710122.001]
  • (PMID = 20592161.001).
  • [ISSN] 1944-9917
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM077253; United States / NIGMS NIH HHS / GM / R01 GM085080; United States / NIGMS NIH HHS / GM / GM 77253; United States / NIGMS NIH HHS / GM / GM 85080
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Double-Stranded; 0 / RNA, Small Interfering; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2999478
  •  go-up   go-down


58. Island ML, Jouanolle AM, Mosser A, Deugnier Y, David V, Brissot P, Loréal O: A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica; 2009 May;94(5):720-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Amino Acid Substitution. Bone Morphogenetic Proteins / pharmacology. Cell Line, Tumor. Gene Expression Regulation / drug effects. Genotype. Hepcidins. Histocompatibility Antigens Class I / genetics. Humans. Luciferases / genetics. Luciferases / metabolism. Male. Membrane Proteins / genetics. Middle Aged. Phenotype. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Response Elements / genetics. Transfection

  • Genetic Alliance. consumer health - Hemochromatosis.
  • MedlinePlus Health Information. consumer health - Hemochromatosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Feb;11(2):555-65 [10679014.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4292-7 [18689548.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7806-10 [11113131.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7811-9 [11113132.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8780-5 [11447267.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):21-2 [12469120.001]
  • [Cites] Lancet. 2003 Feb 22;361(9358):669-73 [12606179.001]
  • [Cites] Blood. 2003 Jul 1;102(1):371-6 [12637325.001]
  • [Cites] Hum Mol Genet. 2003 Sep 1;12(17):2241-7 [12915468.001]
  • [Cites] Hepatology. 2004 Jan;39(1):21-9 [14752817.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2835-40 [14670915.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1913-8 [15254010.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2181-3 [15198949.001]
  • [Cites] Mol Cell Biol. 1993 Apr;13(4):2342-53 [8455616.001]
  • [Cites] Hepatology. 1994 Jul;20(1 Pt 1):15-20 [8020885.001]
  • [Cites] Eur J Clin Nutr. 1997 Nov;51(11):782-6 [9368814.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Jun;18(2):235-50 [15737887.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2922-3 [16204153.001]
  • [Cites] Cell Metab. 2005 Dec;2(6):399-409 [16330325.001]
  • [Cites] Nat Genet. 2006 May;38(5):531-9 [16604073.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2569-78 [17475779.001]
  • [Cites] Blood Rev. 2008 Jul;22(4):195-210 [18430498.001]
  • [Cites] J Mol Med (Berl). 2008 May;86(5):531-40 [18421430.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1465; author reply 1465-6 [19794094.001]
  • [CommentIn] Haematologica. 2010 Apr;95(4):687-8 [20007134.001]
  • (PMID = 19286879.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Bone Morphogenetic Proteins; 0 / HAMP protein, human; 0 / HFE protein, human; 0 / Hepcidins; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / Recombinant Fusion Proteins; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2675685
  •  go-up   go-down


59. Schwemmer M, Sommer O, Bassenge E: Blockade of angiotensin signaling improves myocardial function in hypercholesterolemia independent of changes in eicosanoid release. Cardiovasc Drugs Ther; 2000 Jun;14(3):317-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the potentially beneficial effects of the specific angiotensin-converting enzyme inhibitor enalapril and the specific angiotensin receptor blocker losartan on cardiac performance, eicosanoid metabolism, and parameters of oxidant stress in hypercholesterolemic animals.
  • Both enalapril and losartan lowered plasma cholesterol levels slightly, but only the angiotensin receptor antagonist effectively suppressed the increased plasma XO activities (from 11.4 +/- 0.7 to 7.6 +/- 2.2 U/L), and at the same time decreased the augmented coronary flow (from 26.0 +/- 1.0 to 23.0 +/- 1.0 mL/min/g tissue) observed in hypercholesterolemic animals.
  • Finally, as expected from control studies using heart preparations from normocholesterolemic guinea pigs, enhanced cardiac release of eicosanoids, prostacyclin, and thromboxane in Chol (0.48 +/- 0.03 and 0.6 +/- 0.1 ng/min/g) was augmented even further by treatment with enalapril (Ena: 1.6 +/- 0.4 and 1.0 +/- 0.1 ng/min/g), but was significantly reduced to or below control levels in losartan-treated animals (Los: 0.4 +/- 0.1 and 0.2 +/- 0.1 ng/min/g).
  • Blockade of angiotensin signaling via angiotensin-converting enzyme inhibition or receptor antagonism--although differentially acting on enhanced cardiac prostanoid metabolism and oxidant stress--efficiently restored proper systolic and diastolic myocardial performance (losartan was more beneficial than enalapril), probably by counterbalancing altered angiotensin II-->angiotensin receptor signaling in the cardiovascular system of hypercholesterolemic animals.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10935154.001).
  • [ISSN] 0920-3206
  • [Journal-full-title] Cardiovascular drugs and therapy
  • [ISO-abbreviation] Cardiovasc Drugs Ther
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Angiotensins; 0 / Cholesterol, Dietary; 0 / Eicosanoids; 0 / Proteins
  •  go-up   go-down


60. Gennarino VA, Sardiello M, Avellino R, Meola N, Maselli V, Anand S, Cutillo L, Ballabio A, Banfi S: MicroRNA target prediction by expression analysis of host genes. Genome Res; 2009 Mar;19(3):481-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA target prediction by expression analysis of host genes.
  • MicroRNAs (miRNAs) are small noncoding RNAs that control gene expression by inducing RNA cleavage or translational inhibition.
  • Most human miRNAs are intragenic and are transcribed as part of their hosting transcription units.
  • We hypothesized that the expression profiles of miRNA host genes and of their targets are inversely correlated and devised a novel procedure, HOCTAR (host gene oppositely correlated targets), which ranks predicted miRNA target genes based on their anti-correlated expression behavior relative to their respective miRNA host genes.
  • HOCTAR is the first tool for systematic miRNA target prediction that utilizes the same set of microarray experiments to monitor the expression of both miRNAs (through their host genes) and candidate targets.
  • We applied the procedure to 178 human intragenic miRNAs and found that it performs better than currently available prediction softwares in pinpointing previously validated miRNA targets.
  • The high-scoring HOCTAR predicted targets were enriched in Gene Ontology categories, which were consistent with previously published data, as in the case of miR-106b and miR-93.
  • By means of overexpression and loss-of-function assays, we also demonstrated that HOCTAR is efficient in predicting novel miRNA targets and we identified, by microarray and qRT-PCR procedures, 34 and 28 novel targets for miR-26b and miR-98, respectively.
  • Overall, we believe that the use of HOCTAR significantly reduces the number of candidate miRNA targets to be tested compared to the procedures based solely on target sequence recognition.
  • Finally, our data further confirm that miRNAs have a significant impact on the mRNA levels of most of their targets.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation / physiology. MicroRNAs / genetics. MicroRNAs / physiology. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Algorithms. Forecasting / methods. Genes. HeLa Cells. Humans. Sequence Analysis, RNA / methods

  • COS Scholar Universe. author profiles.
  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2008 Jan 18;29(1):1-7 [18206964.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):58-63 [18668040.001]
  • [Cites] EMBO J. 2008 Feb 6;27(3):471-81 [18256698.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Mar;9(3):219-30 [18270516.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2167-74 [18212054.001]
  • [Cites] Nat Rev Genet. 2008 Apr;9(4):291-302 [18347592.001]
  • [Cites] Physiol Genomics. 2008 Apr 22;33(2):139-47 [18303086.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Cell. 2008 Aug 8;134(3):521-33 [18692474.001]
  • [Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):191-9 [15272480.001]
  • [Cites] Genome Res. 2004 Oct;14(10A):1902-10 [15364901.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e363 [15502875.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] RNA. 2005 Mar;11(3):241-7 [15701730.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Nat Genet. 2005 May;37(5):495-500 [15806104.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):766-70 [15965474.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] RNA. 2006 Feb;12(2):192-7 [16373484.001]
  • [Cites] Trends Genet. 2006 Mar;22(3):165-73 [16446010.001]
  • [Cites] Nat Genet. 2006 Jun;38 Suppl:S8-13 [16736023.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):849-51 [16921378.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Feb;48(2):509-15 [17251443.001]
  • [Cites] EMBO J. 2007 Feb 7;26(3):775-83 [17255951.001]
  • [Cites] Drug Discov Today. 2007 Jun;12(11-12):452-8 [17532529.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):753-67 [17560377.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W193-200 [17478515.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]
  • [Cites] Nat Methods. 2007 Dec;4(12):1045-9 [18026111.001]
  • [Cites] Methods. 2008 Jan;44(1):47-54 [18158132.001]
  • [Cites] BMC Bioinformatics. 2007;8:426 [17980028.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):64-71 [18668037.001]
  • [Cites] Trends Biotechnol. 2008 Feb;26(2):70-6 [18191262.001]
  • (PMID = 19088304.001).
  • [ISSN] 1088-9051
  • [Journal-full-title] Genome research
  • [ISO-abbreviation] Genome Res.
  • [Language] eng
  • [Grant] Italy / Telethon / / TGM06D01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2661810
  •  go-up   go-down


61. Ramadoss J, Lunde ER, Piña KB, Chen WJ, Cudd TA: All three trimester binge alcohol exposure causes fetal cerebellar purkinje cell loss in the presence of maternal hypercapnea, acidemia, and normoxemia: ovine model. Alcohol Clin Exp Res; 2007 Jul;31(7):1252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Alcohol Drinking / psychology. Cerebellum / drug effects. Disease Models, Animal. Ethanol / pharmacology. Fetal Alcohol Spectrum Disorders / etiology. Gestational Age. Pregnancy Complications / psychology
  • [MeSH-minor] Acidosis / pathology. Animals. Cell Count. Female. Hydrogen-Ion Concentration. Hypercapnia / etiology. Hypercapnia / metabolism. Oxygen / blood. Pregnancy. Purkinje Cells / drug effects. Purkinje Cells / pathology. Rats. Sheep

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Fetal Alcohol Spectrum Disorders.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511745.001).
  • [ISSN] 0145-6008
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA10940
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol; S88TT14065 / Oxygen
  •  go-up   go-down


62. Otto M, Barfield RC, Iyengar R, Gatewood J, Müller I, Holladay MS, Houston J, Leung W, Handgretinger R: Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother; 2005 Jan-Feb;28(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, the authors developed a clinical-scale, automated cell purification method for the efficient enrichment of gammadelta T cells from leukapheresis products.
  • Six leukapheresis products were purified for gammadelta T cells using a single-step immunomagnetic method.
  • The mean percentage of gammadelta T cells in the final product was 91%, with an average recovery of 63%.
  • In some products an unusually high proportion of Vgamma9Vdelta1 T cells was found.
  • [MeSH-minor] Blood Donors. Cell Line, Tumor. Cytotoxicity Tests, Immunologic. Hematopoietic Stem Cell Mobilization. Humans. Immunomagnetic Separation / methods. Immunophenotyping. Immunotherapy, Adoptive / methods. Leukapheresis. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614047.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Antigen, T-Cell, gamma-delta; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


63. Chung J, Mujeeb A, Jiang Y, Guilbert C, Pendke M, Wu Y, James TL: A small molecule, Lys-Ala-7-amido-4-methylcoumarin, facilitates RNA dimer maturation of a stem-loop 1 transcript in vitro: structure-activity relationship of the activator. Biochemistry; 2008 Aug 5;47(31):8148-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The type 1 human immunodeficiency virus (HIV-1), like all retroviruses, contains two copies of the RNA genome as a dimer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616287.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI046967; United States / NIAID NIH HHS / AI / AI46967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coumarins; 0 / RNA, Viral
  •  go-up   go-down


64. Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A: Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J; 2009 Feb;9(1):49-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CYP3A locus encodes hepatic enzymes that metabolize many clinically used drugs.
  • However, there is marked interindividual variability in enzyme expression and clearance of drugs metabolized by these enzymes.
  • We investigated the association between these htSNPs and in vivo CYP3A enzyme activity using a single-point IV midazolam clearance assay.

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Midazolam .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1999 Dec;56(6):1329-39 [10570062.001]
  • [Cites] Clin Pharmacol Ther. 2000 Mar;67(3):242-8 [10741627.001]
  • [Cites] Biol Pharm Bull. 2007 Nov;30(11):2091-7 [17978482.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14717-21 [10799560.001]
  • [Cites] Pharmacogenetics. 2000 Jul;10(5):373-88 [10898107.001]
  • [Cites] J Clin Pharmacol. 2000 Nov;40(11):1274-9 [11075313.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3014-23 [11114890.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):383-91 [11279519.001]
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1399-406 [11723248.001]
  • [Cites] Eur J Biochem. 2001 Dec;268(24):6346-58 [11737189.001]
  • [Cites] Eur J Pharm Sci. 2002 Feb;15(1):89-96 [11803135.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):121-32 [11875366.001]
  • [Cites] Mol Pharmacol. 2002 Jul;62(1):162-72 [12065767.001]
  • [Cites] Mol Pharmacol. 2002 Aug;62(2):359-65 [12130689.001]
  • [Cites] Drug Metab Dispos. 2002 Dec;30(12):1491-6 [12433824.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:203-6 [12505311.001]
  • [Cites] Br J Clin Pharmacol. 2003 Mar;55(3):264-9 [12630976.001]
  • [Cites] Drug Metab Dispos. 2003 Jun;31(6):755-61 [12756208.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3576-9 [12824369.001]
  • [Cites] J Appl Physiol (1985). 2003 Sep;95(3):1297-300 [12754175.001]
  • [Cites] Eur J Clin Pharmacol. 2003 Sep;59(5-6):471-6 [12937874.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):585-7 [14515056.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] Mol Pharmacol. 2004 Feb;65(2):326-34 [14742674.001]
  • [Cites] Pharmacogenetics. 2003 Oct;13(10):595-606 [14515058.001]
  • [Cites] Pharmacogenetics. 2004 Apr;14(4):255-60 [15083070.001]
  • [Cites] Drug Metab Dispos. 2004 May;32(5):525-35 [15100175.001]
  • [Cites] Drug Metab Pharmacokinet. 2004 Apr;19(2):120-9 [15499178.001]
  • [Cites] Am J Hum Genet. 2004 Dec;75(6):1059-69 [15492926.001]
  • [Cites] Biochem Pharmacol. 1988 Jul 1;37(13):2507-10 [3390213.001]
  • [Cites] Mol Pharmacol. 1990 Aug;38(2):207-13 [2385232.001]
  • [Cites] Crit Rev Toxicol. 1992;22(1):1-21 [1616599.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jul;270(1):414-23 [8035341.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Oct;271(1):557-66 [7965756.001]
  • [Cites] Mol Cell Biol. 1995 Jun;15(6):3012-22 [7539101.001]
  • [Cites] Mol Pharmacol. 1996 Jul;50(1):52-9 [8700118.001]
  • [Cites] J Pharmacokinet Biopharm. 1996 Oct;24(5):475-90 [9131486.001]
  • [Cites] Ther Drug Monit. 1998 Jun;20(3):319-24 [9631930.001]
  • [Cites] J Clin Invest. 1998 Sep 1;102(5):1016-23 [9727070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12208-13 [9770465.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:1-17 [10331074.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 27;259(1):201-5 [10334940.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8461-7 [15548719.001]
  • [Cites] Hypertension. 2005 Feb;45(2):294-8 [15596575.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Feb;60(12):865-73 [15657782.001]
  • [Cites] Clin Pharmacol Ther. 2005 May;77(5):373-87 [15900284.001]
  • [Cites] Clin Pharmacol Ther. 2005 May;77(5):415-26 [15900287.001]
  • [Cites] Drug Metab Dispos. 2005 Jul;33(7):884-7 [15833928.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):71-80 [16027049.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7398-404 [16243813.001]
  • [Cites] Clin Pharmacol Ther. 2005 Nov;78(5):529-39 [16321619.001]
  • [Cites] Pharmacogenet Genomics. 2006 Jan;16(1):59-71 [16344723.001]
  • [Cites] PLoS Genet. 2005 Dec;1(6):e82 [16429165.001]
  • [Cites] Pharmacogenomics J. 2006 Mar-Apr;6(2):105-14 [16314882.001]
  • [Cites] Clin Pharmacol Ther. 2006 Apr;79(4):350-61 [16580903.001]
  • [Cites] J Hypertens. 2006 May;24(5):923-9 [16612255.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Aug;62(8):653-9 [16832678.001]
  • [Cites] Anesthesiology. 2007 Apr;106(4):652-4 [17413899.001]
  • [Cites] Hypertension. 2007 May;49(5):1007-14 [17372036.001]
  • (PMID = 18825162.001).
  • [ISSN] 1473-1150
  • [Journal-full-title] The pharmacogenomics journal
  • [ISO-abbreviation] Pharmacogenomics J.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060346; United States / NIGMS NIH HHS / GM / GM061393-05; United States / NIGMS NIH HHS / GM / T32 GM007019-28; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NIGMS NIH HHS / GM / R01 GM060346-05; United States / NIGMS NIH HHS / GM / U01 GM061393-05; United States / NIGMS NIH HHS / GM / T32 GM007019; United States / NIGMS NIH HHS / GM / GM07019; United States / NIGMS NIH HHS / GM / T32 GM007019-27; United States / NHLBI NIH HHS / HL / K23 HL089808; United States / NHLBI NIH HHS / HL / K23 HL089808-01A2; United States / NIGMS NIH HHS / GM / R01 GM060346-06; United States / NIGMS NIH HHS / GM / GM61393; None / None / / U01 GM061393-06; United States / NIGMS NIH HHS / GM / GM007019-27; United States / NIGMS NIH HHS / GM / GM60346; United States / NIGMS NIH HHS / GM / GM007019-28; United States / NIGMS NIH HHS / GM / U01 GM061393-06; United States / NIGMS NIH HHS / GM / GM060346-05; United States / NIGMS NIH HHS / GM / GM060346-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; R60L0SM5BC / Midazolam
  • [Other-IDs] NLM/ NIHMS103713; NLM/ PMC2754748
  •  go-up   go-down


65. Hutchinson MR, Somogyi AA: (S)-(+)-methadone is more immunosuppressive than the potent analgesic (R)-(--)-methadone. Int Immunopharmacol; 2004 Nov;4(12):1525-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant analgesia was observed in animals that received racemic methadone (P=0.0012, 52% MPE) and (R)-(--)-methadone (P=0.0002, 70% MPE) when compared to saline-treated controls, while (S)-(+)-methadone was devoid of any such effect (-4% MPE).
  • [MeSH-major] Analgesics, Opioid / pharmacology. Immunosuppressive Agents / pharmacology. Methadone / pharmacology. Pain / drug therapy
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Cells, Cultured. Disease Models, Animal. Male. Mice. Mice, Inbred BALB C. Spleen / cytology. Spleen / immunology. Stereoisomerism

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHADONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15351321.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Immunosuppressive Agents; UC6VBE7V1Z / Methadone
  •  go-up   go-down


66. Cipolli C, Campana G, Campi C, Mattarozzi K, Mazzetti M, Tuozzi G, Vandi S, Vignatelli L, Plazzi G: Sleep and time course of consolidation of visual discrimination skills in patients with narcolepsy-cataplexy. J Sleep Res; 2009 Jun;18(2):209-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If sleep plays an important role in the consolidation process the advantage it provides should be reduced or delayed when its organization is altered, as in patients with chronic sleep disorders.
  • Twenty-two drug-naive NC patients and 22 individually-matched controls underwent training at a texture discrimination task (TDT) and were re-tested on the next morning (after a night spent in laboratory with polysomnography) and after another six nights (spent at home).
  • Moreover, the less-improving patients at next-day retrieval had a wider disorganization of sleep, probably because of an episode of rapid eye movement (REM) sleep at sleep onset REM, on post-training night more frequently than more-improving patients.
  • [MeSH-minor] Adult. Female. Field Dependence-Independence. Humans. Male. Orientation. Polysomnography. Reference Values. Sleep, REM

  • Genetic Alliance. consumer health - Cataplexy.
  • Genetic Alliance. consumer health - Narcolepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302342.001).
  • [ISSN] 1365-2869
  • [Journal-full-title] Journal of sleep research
  • [ISO-abbreviation] J Sleep Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


67. Delgado MA, Poschet JF, Deretic V: Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells. Infect Immun; 2006 May;74(5):2975-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The full repertoire of Pseudomonas products that promote inflammation in the cystic fibrosis lung is not known.
  • Our findings also show that treatments with drugs diminishing organellar acidification may reduce the inflammatory response in cystic fibrosis.


68. Hasan NA: Effects of trace elements on albumin and lipoprotein glycation in diabetic retinopathy. Saudi Med J; 2009 Oct;30(10):1263-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Cadmium / blood. Cadmium / pharmacology. Chromium / blood. Chromium / pharmacology. Copper / blood. Copper / pharmacology. Disease Progression. Glycosylation. Humans. Iraq. Lipoproteins, LDL / blood. Lipoproteins, LDL / drug effects. Oxidative Stress / drug effects. Reference Values. Selenium / blood. Selenium / pharmacology. Zinc / blood. Zinc / pharmacology

  • MedlinePlus Health Information. consumer health - Diabetic Eye Problems.
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838431.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Lipoproteins; 0 / Lipoproteins, LDL; 0 / Serum Albumin; 0 / Trace Elements; 00BH33GNGH / Cadmium; 0R0008Q3JB / Chromium; 789U1901C5 / Copper; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc
  •  go-up   go-down


69. Sawada N, Itoh H, Nakao K: [Stroke prevention by statins]. Nihon Rinsho; 2002 May;60(5):993-1001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The correlation between stroke incidence and serum lipid level has been equivocal, and conventional lipid-lowering agents such as fibrates were ineffective for stroke prevention.
  • [MeSH-major] Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Hypolipidemic Agents / therapeutic use. Stroke / prevention & control
  • [MeSH-minor] Aged. Coronary Disease / drug therapy. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Statins.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12030004.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Hypolipidemic Agents
  • [Number-of-references] 25
  •  go-up   go-down


70. Zhang JB, Wang LL, Lü M, Liu LY, Li D: [Effects of acupuncture at different acupoints on behaviors in depression model rats]. Zhongguo Zhen Jiu; 2005 Sep;25(9):639-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy adult male rats with similar Open-Field score were randomly divided into a normal control group, a model group, a blank control group, a drug treatment group, an acupuncture group I ["Baihui" (GV 20), "Shenting" (GV 24)], II ]"Neiguan" (PC 6), "Sanyinjiao" (SP 6)], and III ("Baihui", "Shenting", "Neiguan" and 'Sanyinjiao"), 10 rats in each group.
  • [MeSH-minor] Acupuncture Therapy. Animals. Depressive Disorder. Humans. Problem Behavior. Rats

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318153.001).
  • [ISSN] 0255-2930
  • [Journal-full-title] Zhongguo zhen jiu = Chinese acupuncture & moxibustion
  • [ISO-abbreviation] Zhongguo Zhen Jiu
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Zhang M, Si L, Jin L, Wang Y, Geng Y: [Construction, eukaryotic expression and biological activities of a recombinant human single chain interleukin-12 fusion gene]. Zhonghua Xue Ye Xue Za Zhi; 2000 Dec;21(12):636-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction, eukaryotic expression and biological activities of a recombinant human single chain interleukin-12 fusion gene].
  • OBJECTIVE: To explore the feasibility of recombinant human interleukin 12 (IL-12) with biological activities by molecular biological techniques.
  • The assays of biological functions showed that the fusion protein had strong bioactivities in stimulating the lymphocyte proliferation, enhancing the NK cell cytotoxicity and increasing the IFN-gamma production.
  • [MeSH-minor] Animals. Blotting, Western. COS Cells. Cell Division / drug effects. Cell Line. Cloning, Molecular. Gene Expression. Genetic Vectors / genetics. Humans. K562 Cells. RNA, Messenger / genetics. RNA, Messenger / metabolism. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Recombinant Fusion Proteins / pharmacology. Transfection

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11877038.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 187348-17-0 / Interleukin-12
  •  go-up   go-down


72. Ioka T, Tasaki H, Yashiro A, Yamashita K, Ozumi K, Tsutsui M, Kouzuma R, Okazaki M, Nakashima Y: Association between plasma lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries. Circ J; 2002 Mar;66(3):267-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acetylcholine / pharmacology. Adult. Aged. Angiography. Cholesterol / blood. Female. Humans. Male. Middle Aged. Nitroglycerin / pharmacology. Predictive Value of Tests. Regression Analysis. Risk Factors. Vasoconstriction / drug effects. Vasodilation / drug effects

  • Hazardous Substances Data Bank. NITROGLYCERIN .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11922276.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Lipoprotein(a); 97C5T2UQ7J / Cholesterol; G59M7S0WS3 / Nitroglycerin; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


73. Arai I, Takano N, Hashimoto Y, Futaki N, Sugimoto M, Takahashi N, Inoue T, Nakaike S: Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol; 2004 Nov 28;505(1-3):229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] 6-Ketoprostaglandin F1 alpha / metabolism. Alprostadil / pharmacology. Animals. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Arachidonic Acid / pharmacology. Behavior, Animal / drug effects. Dinoprost / metabolism. Dinoprostone / metabolism. Dinoprostone / pharmacology. Dose-Response Relationship, Drug. Epoprostenol / pharmacology. Histamine / administration & dosage. Indomethacin / pharmacology. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Skin / drug effects. Skin / metabolism. Skin / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Itching.
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15556157.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 6-keto-prostaglandin F2alpha; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Prostaglandins; 0 / Receptors, Prostaglandin; 27YG812J1I / Arachidonic Acid; 58962-34-8 / 6-Ketoprostaglandin F1 alpha; 60203-57-8 / 9-deoxy-delta-9-prostaglandin D2; 820484N8I3 / Histamine; B7IN85G1HY / Dinoprost; DCR9Z582X0 / Epoprostenol; F5TD010360 / Alprostadil; K7Q1JQR04M / Dinoprostone; RXY07S6CZ2 / Prostaglandin D2; XXE1CET956 / Indomethacin
  •  go-up   go-down


74. Shreffler WG, Visness CM, Burger M, Cruikshank WW, Lederman HM, de la Morena M, Grindle K, Calatroni A, Sampson HA, Gern JE: Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study. BMC Immunol; 2006 Dec 12;7:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardization and performance evaluation of mononuclear cell cytokine secretion assays in a multicenter study.
  • BACKGROUND: Cryopreservation of peripheral blood mononuclear cells has been used to preserve and standardize immunologic measurements for multicenter studies, however, effects of cryopreservation on cytokine responses are incompletely understood.
  • In designing immunologic studies for a new multicenter birth cohort study of childhood asthma, we performed a series of experiments to determine the effects of two different methods of cryopreservation on the cytokine responses of cord and peripheral blood mononuclear cells.
  • RESULTS: Paired samples of PBMC were processed freshly, or after cryopreservation in a Nalgene container (NC) or a controlled-rate freezer (CRF).
  • Although there were some differences between the methods, cryopreservation inhibited PHA-induced IL-10 secretion and Der f 1-induced IL-2 secretion, and augmented PHA-induced IL-2 secretion and spontaneous secretion of TNF-alpha.
  • In separate experiments, NC cryopreservation inhibited secretion of several cytokines (IL-13, IL-10, IFN-gamma, TNF-alpha) by PHA-stimulated cord blood mononuclear cells.
  • With the exception of PHA-induced IL-13, results from fresh and cryopreserved cord blood samples were not significantly correlated.
  • Finally, in reproducibility studies involving processing of identical cell samples in up to 4 separate laboratories, variances in cytokine responses of fresh cells stimulated at separate sites did not exceed those in cryopreserved cells stimulated at a central site.
  • CONCLUSION: Collectively, these studies indicate that cryopreservation can affect mononuclear cell cytokine response profiles, and that IL-10 secretion and antigen-induced responses may be especially vulnerable.
  • These studies also demonstrate that mononuclear cell responses can be standardized for performance in a small number of laboratories for multicenter studies, and underscore the importance of measuring reproducibility and of testing whether cryopreservation techniques alter specific immunologic outcomes.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Diagn Lab Immunol. 2000 May;7(3):352-9 [10799445.001]
  • [Cites] J Immunol Methods. 2006 Jan 20;308(1-2):13-8 [16337957.001]
  • [Cites] J Immunol Methods. 2001 Sep 1;255(1-2):27-40 [11470284.001]
  • [Cites] J Immunol Methods. 2002 Dec 1;270(1):99-108 [12379342.001]
  • [Cites] J Immunol Methods. 2003 Jul;278(1-2):79-93 [12957398.001]
  • [Cites] J Immunol Methods. 2003 Jul;278(1-2):145-55 [12957403.001]
  • [Cites] Int J Cancer. 1976 Aug 15;18(2):145-55 [133996.001]
  • [Cites] J Clin Lab Immunol. 1982 Apr;7(3):205-13 [6980285.001]
  • [Cites] J Leukoc Biol. 1984 Oct;36(4):521-31 [6090557.001]
  • [Cites] Biometrics. 1989 Mar;45(1):255-68 [2720055.001]
  • [Cites] J Hematother. 1996 Jun;5(3):301-8 [8817398.001]
  • [Cites] J Immunol Methods. 1997 Apr 11;203(1):1-10 [9134025.001]
  • [Cites] Scand J Immunol. 1997 Jun;45(6):618-22 [9201301.001]
  • [Cites] Clin Diagn Lab Immunol. 1998 Nov;5(6):804-7 [9801338.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Jan;6(1):14-9 [9874657.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jan;21(1):68-81 [15665646.001]
  • [Cites] BMC Immunol. 2005;6:17 [16026627.001]
  • [Cites] Clin Diagn Lab Immunol. 2000 Jul;7(4):714-6 [10882680.001]
  • (PMID = 17156490.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / N01AI25482; United States / NIAID NIH HHS / AI / N01AI25496; United States / NIAID NIH HHS / AI / N01-AI-25482; United States / NIAID NIH HHS / AI / N01-AI-25496
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; 0 / Cytokines; 0 / Lipopolysaccharides; 0 / Mitogens; 0 / Phytohemagglutinins
  • [Other-IDs] NLM/ PMC1762025
  •  go-up   go-down


75. Epperlein HH, Radomski N, Wonka F, Walther P, Wilsch M, Müller M, Schwarz H: Immunohistochemical demonstration of hyaluronan and its possible involvement in axolotl neural crest cell migration. J Struct Biol; 2000 Oct;132(1):19-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effect of hyaluronan on neural crest (NC) cell migration and its ultrastructural localization in dark (wild-type) and white mutant embryos of the Mexican axolotl (Ambystoma mexicanum, Amphibia).
  • [MeSH-minor] Animals. Basement Membrane / chemistry. Basement Membrane / ultrastructure. Cell Movement / drug effects. Cell Movement / physiology. Cryopreservation. Extracellular Matrix / chemistry. Extracellular Matrix / ultrastructure. Immunohistochemistry. Microscopy, Electron / methods. Tissue Fixation

  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11121304.001).
  • [ISSN] 1047-8477
  • [Journal-full-title] Journal of structural biology
  • [ISO-abbreviation] J. Struct. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


76. Arruzazabala ML, Molina V, Carbajal D, Fernández L, Mas R, Castaño G, Illnait J, Mendoza S, Fernańdez J: Effects of D-003, a mixture of very long chain fatty acids purified from sugar cane wax, at 5 and 10 mg/day on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res; 2005;25(1):29-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of D-003, a mixture of very long chain fatty acids purified from sugar cane wax, at 5 and 10 mg/day on platelet aggregation in healthy volunteers.
  • D-003 is a mixture of high molecular weight aliphatic primary acids purified from sugar cane wax with antiplatelet and cholesterol-lowering effects.
  • [MeSH-major] Fatty Acids / pharmacology. Platelet Aggregation / drug effects. Platelet Aggregation Inhibitors / pharmacology
  • [MeSH-minor] Administration, Oral. Adult. Blood Cell Count. Cholesterol / blood. Double-Blind Method. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868655.001).
  • [ISSN] 0251-1649
  • [Journal-full-title] International journal of clinical pharmacology research
  • [ISO-abbreviation] Int J Clin Pharmacol Res
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / D-003 sugarcane wax acid mixture; 0 / Fatty Acids; 0 / Platelet Aggregation Inhibitors; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


77. Wang Q, Li YJ, Lu BX: [Effects of thyroid hormone on cognitive function in rats with chronic cerebral ischemia]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Jan;25(1):106-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Ischemia / drug therapy. Cognition / drug effects. Cognition Disorders / drug therapy. Thyroid Hormones / therapeutic use
  • [MeSH-minor] Animals. Chronic Disease. Male. Maze Learning / drug effects. Random Allocation. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15684013.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Thyroid Hormones
  •  go-up   go-down


78. Coyle AT, Miggin SM, Kinsella BT: Characterization of the 5' untranslated region of alpha and beta isoforms of the human thromboxane A2 receptor (TP). Differential promoter utilization by the TP isoforms. Eur J Biochem; 2002 Aug;269(16):4058-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proximity of P3 to the TI site of TPbeta suggests a role for P3 in the control of TPbeta expression and implies that TPalpha and TPbeta, in addition to being products of differential splicing, are under the transcriptional control of distinct promoters.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12180983.001).
  • [ISSN] 0014-2956
  • [Journal-full-title] European journal of biochemistry
  • [ISO-abbreviation] Eur. J. Biochem.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Thromboxane; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


79. Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E: Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res; 2004 Apr 1;10(7):2570-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.
  • This study investigated which chemopreventive agents activated this degradation program and whether cyclin E was also degraded.
  • (b) cyclin degradation occurred in derived BEAS-2B-R1 cells that were partially resistant to RA; and (c) other candidate chemopreventive agents caused cyclin degradation.
  • Transfection experiments in BEAS-2B cells indicated that RA treatment repressed expression of wild-type cyclin D1 and cyclin E, but ALLN inhibited this degradation.
  • Specific chemopreventive agents triggered cyclin degradation.
  • CONCLUSIONS: Specific chemopreventive agents activate cyclin proteolysis.
  • Yet, broad resistance did not occur after acquired resistance to a single agent.
  • This provides a therapeutic rationale for combination chemoprevention with agents activating non-cross-resistant pathways.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclins / metabolism. Proteasome Endopeptidase Complex / metabolism
  • [MeSH-minor] Bronchi / cytology. Cell Culture Techniques. Cell Division. Cell Line. Cyclin D1 / biosynthesis. Cyclin D1 / metabolism. Cyclin E / metabolism. Cyclin G. Cyclin G1. DNA Damage. Dose-Response Relationship, Drug. Epithelial Cells / metabolism. G1 Phase. Humans. Immunoblotting. Leupeptins / pharmacology. Mutation. Proteasome Inhibitors. Retinoids / chemistry. Reverse Transcriptase Polymerase Chain Reaction. Threonine / chemistry. Transcription, Genetic. Transfection. Tretinoin / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. L-Threonine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2004 Apr 1;10(7):2220-1 [15073095.001]
  • (PMID = 15073138.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09658; United States / NCI NIH HHS / CA / R01-CA 87546; United States / NCI NIH HHS / CA / T32-CA09658
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / CCNG1 protein, human; 0 / Cyclin E; 0 / Cyclin G; 0 / Cyclin G1; 0 / Cyclins; 0 / Leupeptins; 0 / Proteasome Inhibitors; 0 / Retinoids; 110044-82-1 / acetylleucyl-leucyl-norleucinal; 136601-57-5 / Cyclin D1; 2ZD004190S / Threonine; 5688UTC01R / Tretinoin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


80. Han X, Liu J, Liu M, Xie C, Zhan C, Gu B, Liu Y, Feng L, Lu W: 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm; 2009 May 8;372(1-2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro.
  • In this study, folate-conjugated polymer micelles were synthesized by mixing folate-poly(ethylene glycol)-distearoylphosphatidylethanolamine (FA-PEG-DSPE) and methoxy-poly(ethylene glycol)-distearoylphosphatidylethanolamine (MPEG-DSPE) to encapsulate anticancer agent 9-nitro-camptothecin (9-NC).
  • Formulations were characterized by critical micellization concentration (CMC) values of copolymers, micelle particle size, zeta-potential, encapsulation efficiency and drug loading efficiency.
  • The drug efficacy in vitro of folate-conjugated polymer micelles was evaluated by using the methylthiazoletetrazolium (MTT) method.
  • The average size of folate-conjugated micelle was about 21-24 nm and the micelle size distribution of both empty and drug-loaded micelles were rather narrow.
  • The encapsulation efficiency and drug loading efficiency were 97.6% and 4.64%, respectively.
  • The drug-loaded micelles were stable during storage at 4 degrees C for 4 weeks.
  • The best molar ratio of FA-PEG-DSPE and MPEG-DSPE in folate-conjugated micelles was 1:100 which can effectively solubilize 9-NC, avoid the macrophages in vitro and has a higher anti-tumor activity than both drug-loaded MPEG-DSPE micelles and free anticancer agents.
  • The folate-conjugated polymer micelle which can avoid the macrophages is a kind of promising carrier for poorly soluble anticancer agents via folate receptor (FR) that mediated endocytosis to target tumor cells.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / analogs & derivatives. Drug Delivery Systems / methods. Folic Acid / administration & dosage. Micelles. Polymers / administration & dosage
  • [MeSH-minor] Cell Line, Tumor. Drug Evaluation, Preclinical / methods. HeLa Cells. Humans. Neoplasms / drug therapy. Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19166923.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Micelles; 0 / Polymers; 935E97BOY8 / Folic Acid; H19C446XXB / rubitecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


81. Terakado N, Shintani S, Nakashiro KI, Hino S, Hamakawa H: [A clinical study of neoadjuvant radiochemotherapy with docetaxel and cisplatin for oral cancers]. Gan To Kagaku Ryoho; 2003 Dec;30(13):2091-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Docetaxel is classified among the microtubule-inhibiting compounds called taxanes, which are currently used as agents to treat head and neck cancers.
  • Of the 6 patients, 5 (83.3%) showed a partial response (PR) and 1 showed no response (NC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neutropenia / chemically induced. Radiotherapy Dosage. Radiotherapy, Adjuvant. Stomatitis / chemically induced. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14712770.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Coles MP, Hitchcock PB, Khvostov AV, Lappert MF, Li Z, Protchenko AV: Crystalline amidocerium(IV) oxides and a side-on bridging dioxygen complex. Dalton Trans; 2010 Aug 7;39(29):6780-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystalline amidocerium(IV) oxides and a side-on bridging dioxygen complex.
  • Complexes [Ce(NR(2))(3)] (1) or [Ce(NR''(2))(3)] (2) were cerium(III) precursors to the X-ray characterised crystalline oligomeric oxygen-containing amidocerium(IV) compounds [{Ce(NR(2))(2)(mu-O)}(n)] (3, n = 2; 4, n = 3), [{Ce(NR''(2))(2)(mu-O)}(4)] (5), [{(R(2)N)(3)Ce}(2)(mu-[upper bond 1 start]OMOM[upper bond 1 end])] (6, M = Na; 7, M = K), [{(R(2)N)(3)CeOCe(NR(2))(2)}(2)(mu-[upper bond 1 start]OKOK[upper bond 1 end])] (8), and [{Ce(NR(2))(3)}(2)(mu-eta(2):eta(2)-O(2))].2C(n)H(2n+2) (9, n = 6; 9', n = 5) [R = SiMe(3), NR''(2) = TMP = [upper bond 1 start]NC(Me)(2)(CH(2))(3)C[upper bond 1 end]Me(2)].
  • Except for 4, the oxidising agent was O(2) at -27 degrees C in hexane (3, 6, 7, 8, 9), pentane (9'), or toluene (5), and a co-reagent for the alkali metal bis(trimethylsilyl)amido(oxy)cerate(iv)s was NaNR(2) (8) or KNR(2) (7, 8).
  • From 1 and an equivalent portion of 2,6-(t)Bu(2)-benzoquinone after 5 weeks in pentane there was obtained the bis(amido)cyclotricer(IV)oxane 4.
  • The NMR spectral solution chemical shifts for NR(2) groups of 3, 4, and 6-9 were consistent with each sample being diamagnetic and hence a Ce(IV) species.
  • A transient amidocerium(IV) superoxide Ce(NR(2))(3)(eta(2)-O(2)) (J), or its TMP analogue, is considered to be the common first-formed intermediate in each case, while 4 is believed to have arisen from the adventitious hydrolysis of [{Ce(NR(2))(3)O}(2)((t)Bu(2)C(6)H(2)-1,4)].

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585693.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Goldman C, Rosser E Jr, Petersen A, Hauptman J: Investigation on the effects of ciclosporin (Atopica) on intradermal test reactivity and allergen-specific immunoglobulin (IgE) serology in atopic dogs. Vet Dermatol; 2010 Aug;21(4):393-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ability to use ciclosporin (Atopica®: Novartis Animal Health, Greensboro, NC, USA) prior to intradermal testing (IDT) would help avoid exacerbation of clinical disease that can be associated with drug withdrawal.
  • [MeSH-minor] Animals. Cross-Over Studies. Dogs. Double-Blind Method. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Intradermal Tests / veterinary

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 ESVD and ACVD.
  • (PMID = 20214766.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Allergens; 0 / Immunosuppressive Agents; 37341-29-0 / Immunoglobulin E; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


84. Sugimoto M, Arai I, Futaki N, Hashimoto Y, Sakurai T, Honma Y, Nakaike S: The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice. Eur J Pharmacol; 2007 Jun 14;564(1-3):196-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TS-022 is a prostanoid DP(1) receptor agonist, originally developed as a novel anti-pruritic drug for atopic dermatitis.
  • The drug has been shown to suppress scratching and improve the skin inflammation in the NC/Nga (NC) mouse, a model of atopic dermatitis.
  • Corticosteroids are commonly used as effective agents for the treatment of atopic dermatitis.
  • While after 2 weeks of cohabitation with skin-lesioned NC mice (early phase of dermatitis, characterized by the appearance of spontaneous scratching), topically applied TS-022 exhibited a weak anti-pruritic effect in the NC mice, after 6 weeks of cohabitation (late phase, characterized by both chronic scratching and dermatitis), the drug exerted potent anti-pruritic activity.
  • [MeSH-major] Acetates / pharmacology. Antipruritics / pharmacology. Cyclohexanes / pharmacology. Dermatitis, Atopic / drug therapy. Prostaglandin D2 / metabolism. Receptors, Prostaglandin / agonists. Sulfhydryl Compounds / pharmacology
  • [MeSH-minor] Animals. Anti-Inflammatory Agents / therapeutic use. Arachidonic Acid. Dexamethasone / therapeutic use. Gene Expression Regulation. Male. Mice. Pruritus / drug therapy. Skin / drug effects. Skin / physiopathology. Water Loss, Insensible

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328887.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / (4-((1R, 2S, 3R, 5R)-5-Chloro-2-((S)-3-cyclohexyl-3-hydroxyprop-1-ynyl)-3-hydroxycyclopentyl) butylthio) acetic acid monohydrate; 0 / Acetates; 0 / Anti-Inflammatory Agents; 0 / Antipruritics; 0 / Cyclohexanes; 0 / Receptors, Prostaglandin; 0 / Sulfhydryl Compounds; 0 / prostanoid D receptor 1, human; 27YG812J1I / Arachidonic Acid; 7S5I7G3JQL / Dexamethasone; RXY07S6CZ2 / Prostaglandin D2
  •  go-up   go-down


85. Wang H, Yang Z, Zhou B, Gao H, Yan X, Wang J: Fluoride-induced thyroid dysfunction in rats: roles of dietary protein and calcium level. Toxicol Ind Health; 2009 Feb;25(1):49-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To assess the roles of dietary protein (Pr) and calcium (Ca) level associated with excessive fluoride (F) intake and the impact of dietary Pr, Ca, and F on thyroid function, 144 30-day-old Wistar albino rats were randomly allotted to six groups of 24 (female:male = 1:1).
  • The six groups were fed (1) a normal control (NC) diet (17.92% Pr, 0.85% Ca = NC group);.
  • (3) low Pr and low Ca diet (10.01% Pr, 0.24% Ca = LPrLCa group);.
  • (4) low Pr and low Ca diet plus high F = LPrLCa+F group;.
  • (5) high Pr and low Ca diet plus high F (25.52% Pr, 0.25% Ca = HPrLCa+F group); and (6) low Pr and high Ca diet plus high F (10.60% Pr, 1.93% Ca = LPrHCa+F group).
  • The histopathological study revealed obviously flatted follicular epithelia cells and hyperplastic nodules, consisting of thyroid parafollicular cells that appeared by excessive F ingestion, on the 120th day.
  • Pr or Ca supplementation reverses the F-induced damage in malnutrition.
  • Thus, excessive F administration induces thyroid dysfunction in rats; dietary Pr and Ca level play key roles in F-induced thyroid dysfunction.
  • [MeSH-major] Calcium, Dietary / administration & dosage. Dietary Proteins / administration & dosage. Sodium Fluoride / toxicity. Thyroid Gland / drug effects. Water Pollutants, Chemical / toxicity
  • [MeSH-minor] Administration, Oral. Animals. Body Weight / drug effects. Drinking. Drug Combinations. Female. Male. Rats. Thyroid Nodule / chemically induced. Thyroid Nodule / pathology. Thyroxine / blood. Triiodothyronine / blood. Weight Gain / drug effects

  • MedlinePlus Health Information. consumer health - Calcium.
  • MedlinePlus Health Information. consumer health - Dietary Proteins.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • Hazardous Substances Data Bank. SODIUM FLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318504.001).
  • [ISSN] 0748-2337
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium, Dietary; 0 / Dietary Proteins; 0 / Drug Combinations; 0 / Water Pollutants, Chemical; 06LU7C9H1V / Triiodothyronine; 8ZYQ1474W7 / Sodium Fluoride; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


86. Caramuta S, De Cecco L, Reid JF, Zannini L, Gariboldi M, Kjeldsen L, Pierotti MA, Delia D: Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR. Int J Cancer; 2006 Oct 1;119(7):1599-606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Acute-Phase Proteins / genetics. Antineoplastic Agents / pharmacology. Fenretinide / pharmacology. Neoplasms / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cytosol / drug effects. Cytosol / metabolism. Down-Regulation / drug effects. Free Radicals / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Lipocalins. RNA, Small Interfering / genetics. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16671099.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Antineoplastic Agents; 0 / Free Radicals; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


87. Zhou J, Zhong DW, Wang QW, Miao XY, Xu XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J Gastroenterol; 2010 Jul 14;16(26):3330-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TGF-beta signaling cascade and status of various extracellular matrix proteins were evaluated by real time reverse transcriptase polymerase chain reaction and Western blotting.
  • [MeSH-major] Hepatic Stellate Cells / drug effects. Liver Cirrhosis / drug therapy. Paclitaxel / pharmacology. Smad Proteins / antagonists & inhibitors. Transforming Growth Factor beta / antagonists & inhibitors
  • [MeSH-minor] Animals. Base Sequence. Cells, Cultured. DNA Primers / genetics. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Recombinant Proteins / pharmacology. Signal Transduction / drug effects. Tubulin Modulators / pharmacology

  • Genetic Alliance. consumer health - Hepatic fibrosis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2000 Jan;5(1):27-34 [10678166.001]
  • [Cites] World J Gastroenterol. 2008 Apr 7;14(13):2100-5 [18395914.001]
  • [Cites] Hepatology. 2002 Jan;35(1):49-61 [11786959.001]
  • [Cites] Front Biosci. 2002 Apr 1;7:d793-807 [11897555.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Circ Res. 2004 Mar 19;94(5):617-25 [14739161.001]
  • [Cites] Nature. 1979 Feb 22;277(5698):665-7 [423966.001]
  • [Cites] Arthritis Rheum. 1994 Jun;37(6):839-45 [7911665.001]
  • [Cites] Lancet. 1994 Nov 5;344(8932):1267-72 [7967989.001]
  • [Cites] Cell Growth Differ. 1994 Oct;5(10):1041-50 [7848905.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Jun;13(6):476-8 [15975296.001]
  • [Cites] Mol Biol Cell. 2005 Sep;16(9):4214-24 [15987742.001]
  • [Cites] PLoS Med. 2005 Dec;2(12):e354 [16250671.001]
  • [Cites] Z Gastroenterol. 2006 Jan;44(1):57-66 [16397841.001]
  • [Cites] J Cell Mol Med. 2006 Jan-Mar;10(1):76-99 [16563223.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2006 Dec;14(12):909-13 [17196135.001]
  • [Cites] Gut. 2007 Feb;56(2):284-92 [17303605.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S79-84 [17567474.001]
  • [Cites] J Neuroimmunol. 2000 Aug 1;108(1-2):103-11 [10900343.001]
  • (PMID = 20614491.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Smad Proteins; 0 / Transforming Growth Factor beta; 0 / Tubulin Modulators; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2900727
  •  go-up   go-down


88. Klingman D, Williams SA, Benner JS, Smith TW, Ahn J, O'Donnell JC: Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J; 2005 Sep;150(3):595-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among 1,425 respondents aged > or = 20 years with complete data, 29.5% were eligible for therapeutic lifestyle changes (TLCs, 16.0%) or lipid-lowering drug therapy (LDT, 13.4%).
  • Of adults eligible for drug therapy, the average percentage reduction in low-density lipoprotein cholesterol (LDL-C) required to reach goal was 28.0% (standard error [SE] 1.1), and 41.9% required a reduction of > 30% in LDL-C to reach goal.
  • Of high-risk adults eligible for drug therapy, the average required reduction was 36.9% (SE 1.4), and 76.3% required a reduction of > 30% in LDL-C.
  • [MeSH-minor] Adult. Female. Health Care Surveys. Humans. Hypolipidemic Agents / therapeutic use. Life Style. Lipids / blood. Male. Middle Aged. Nutrition Surveys. Quality of Health Care. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169347.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypolipidemic Agents; 0 / Lipids
  •  go-up   go-down


89. Su YP, Tang JM, Tang Y, Gao HY: Histological and ultrastructural changes induced by selenium in early experimental gastric carcinogenesis. World J Gastroenterol; 2005 Aug 7;11(29):4457-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Eosinophils / pathology. Eosinophils / ultrastructure. Gastric Mucosa / pathology. Gastric Mucosa / ultrastructure. Incidence. Male. Microscopy, Electron. Parietal Cells, Gastric / pathology. Parietal Cells, Gastric / ultrastructure. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052671.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] H6241UJ22B / Selenium
  • [Other-IDs] NLM/ PMC4398691
  •  go-up   go-down


90. Joyce S: Immune recognition, response, and regulation: how T lymphocytes do it. Immunol Res; 2001;23(2-3):215-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effective immunity to infectious agents requires the initial recognition of antigen by specific receptors, which leads to the activation of immunocytes and the elicitation of an immune response.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigen Presentation. Antigens, CD1d. Antiporters / deficiency. Antiporters / physiology. Cytokines / physiology. Endoplasmic Reticulum / metabolism. Golgi Apparatus / metabolism. H-2 Antigens / immunology. Humans. Immunoglobulins / deficiency. Immunoglobulins / physiology. Killer Cells, Natural / immunology. Ligands. Lipids / immunology. Lymphocyte Activation. Membrane Transport Proteins. Mice. Mice, Knockout. Models, Immunological. Molecular Sequence Data. Protein Conformation. Protein Transport. Receptors, Antigen, T-Cell / immunology. Sequence Alignment. Sequence Homology, Amino Acid. T-Lymphocytes, Cytotoxic / immunology. Thymus Gland / cytology

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Feb 9;84(3):389-94 [8608592.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3121-7 [9531266.001]
  • [Cites] Nature. 1990 Jan 18;343(6255):275-8 [1689009.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):331-6 [9221763.001]
  • [Cites] Cell Immunol. 2000 Jan 10;199(1):37-42 [10675273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7411-6 [10840051.001]
  • [Cites] J Exp Med. 2000 Mar 20;191(6):907-14 [10727453.001]
  • [Cites] Science. 1994 Mar 25;263(5154):1774-8 [7907820.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2373-7 [10452969.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3753-6 [10201888.001]
  • [Cites] Nature. 1990 Aug 2;346(6283):476-80 [2198471.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1541-4 [9488653.001]
  • [Cites] J Immunol. 1996 Jun 1;156(11):4182-90 [8666786.001]
  • [Cites] Chem Immunol. 1993;57:39-62 [8260089.001]
  • [Cites] Science. 1981 Jul 10;213(4504):172-8 [7017931.001]
  • [Cites] J Virol. 2000 Aug;74(15):6922-34 [10888631.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):579-88 [8294869.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):103-10 [9874567.001]
  • [Cites] Annu Rev Immunol. 1999;17:51-88 [10358753.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5005-9 [10799852.001]
  • [Cites] J Immunol. 1997 Dec 15;159(12):5931-5 [9550390.001]
  • [Cites] Curr Opin Immunol. 1994 Feb;6(1):24-31 [7513524.001]
  • [Cites] J Exp Med. 1991 Nov 1;174(5):1059-71 [1940788.001]
  • [Cites] Oncol Res. 1995;7(10-11):529-34 [8866665.001]
  • [Cites] J Immunol. 2001 Apr 1;166(7):4370-9 [11254691.001]
  • [Cites] J Exp Med. 1992 Jan 1;175(1):163-8 [1309852.001]
  • [Cites] J Mol Biol. 1997 Mar 14;266(5):993-1001 [9086276.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4719-27 [9794402.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4413-20 [10510382.001]
  • [Cites] Int Immunol. 1996 Nov;8(11):1759-66 [8943571.001]
  • [Cites] J Exp Med. 1992 Mar 1;175(3):719-29 [1311017.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1626-9 [9374463.001]
  • [Cites] Annu Rev Biochem. 1989;58:635-69 [2673019.001]
  • [Cites] Cell Immunol. 1977 Mar 1;29(1):1-5 [300293.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10156-61 [10963678.001]
  • [Cites] J Mol Biol. 1991 May 20;219(2):277-319 [2038058.001]
  • [Cites] J Virol. 1995 Nov;69(11):6665-77 [7474076.001]
  • [Cites] Curr Opin Immunol. 1995 Jun;7(3):367-74 [7546402.001]
  • [Cites] J Exp Med. 2000 Mar 6;191(5):771-80 [10704459.001]
  • [Cites] Science. 1995 May 12;268(5212):863-5 [7538697.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):59-64 [10881176.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):248-51 [2234092.001]
  • [Cites] Annu Rev Immunol. 1999;17:369-97 [10358763.001]
  • [Cites] Science. 1997 Jul 18;277(5324):339-45 [9219685.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):2091-6 [7500054.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:459-85 [9891790.001]
  • [Cites] Cell Immunol. 1995 Jan;160(1):33-42 [7842484.001]
  • [Cites] Bone Marrow Transplant. 1991 Sep;8(3):217-23 [1958902.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1623-6 [9374462.001]
  • [Cites] Eur J Immunol. 2000 Feb;30(2):620-5 [10671219.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5094-8 [10227978.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):234-8 [10973281.001]
  • [Cites] Adv Immunol. 1995;59:1-98 [7484459.001]
  • [Cites] Annu Rev Immunol. 1995;13:587-622 [7612235.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2240-9 [9278312.001]
  • [Cites] Eur J Immunol. 1999 Jun;29(6):2014-25 [10382765.001]
  • [Cites] Immunity. 1998 Nov;9(5):669-76 [9846488.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1285-95 [7908323.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1011-9 [9215624.001]
  • [Cites] Trends Immunol. 2001 Apr;22(4):194-9 [11274924.001]
  • [Cites] Immunity. 1998 Sep;9(3):345-53 [9768754.001]
  • [Cites] Immunol Rev. 1999 Dec;172:21-8 [10631934.001]
  • [Cites] Immunity. 1997 Apr;6(4):469-77 [9133426.001]
  • [Cites] J Cell Biol. 1989 Jul;109(1):61-72 [2745557.001]
  • [Cites] Immunol Today. 2000 Nov;21(11):573-83 [11094262.001]
  • [Cites] Nature. 1991 May 23;351(6324):290-6 [1709722.001]
  • [Cites] Annu Rev Cell Dev Biol. 1995;11:267-306 [8689559.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1395-401 [9126920.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):4647-50 [10528160.001]
  • [Cites] Immunity. 2000 Aug;13(2):213-22 [10981964.001]
  • [Cites] Immunol Rev. 1996 Dec;154:59-103 [9034864.001]
  • [Cites] Cell Mol Life Sci. 2001 Mar;58(3):442-69 [11315191.001]
  • [Cites] J Immunol. 1992 May 15;148(10):3004-11 [1374446.001]
  • [Cites] Immunity. 2000 Feb;12(2):211-21 [10714687.001]
  • (PMID = 11444386.001).
  • [ISSN] 0257-277X
  • [Journal-full-title] Immunologic research
  • [ISO-abbreviation] Immunol. Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 42284; United States / NHLBI NIH HHS / HL / HL 54977
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Antigens, CD1d; 0 / Antiporters; 0 / CD1D protein, human; 0 / Cytokines; 0 / H-2 Antigens; 0 / Histocompatibility Antigens Class I; 0 / Immunoglobulins; 0 / Ligands; 0 / Lipids; 0 / Membrane Transport Proteins; 0 / Receptors, Antigen, T-Cell; 0 / tapasin
  • [Number-of-references] 75
  •  go-up   go-down


91. Domaica CI, Fuertes MB, Rossi LE, Girart MV, Avila DE, Rabinovich GA, Zwirner NW: Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands. EMBO Rep; 2009 Aug;10(8):908-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / physiology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / physiology. Cell Line, Tumor. Cells, Cultured. Flow Cytometry. Humans. Interferon-gamma / metabolism. Interleukin-2 / pharmacology. Microscopy, Confocal. Mitogens / pharmacology. Phytohemagglutinins / pharmacology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism. T-Lymphocytes / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):1-4 [11751938.001]
  • [Cites] FASEB J. 2002 Apr;16(6):477-86 [11919150.001]
  • [Cites] J Immunol. 2003 Jan 15;170(2):805-15 [12517944.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8 [10411927.001]
  • [Cites] Semin Immunol. 2006 Jun;18(3):151-8 [16730454.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):4606-14 [18354183.001]
  • [Cites] J Immunol. 2007 Mar 15;178(6):3637-47 [17339461.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1423-33 [17318190.001]
  • [Cites] Annu Rev Immunol. 2007;25:267-96 [17134371.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1568-76 [17641023.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):737-44 [17673918.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3472-9 [17804388.001]
  • [Cites] J Immunol. 2007 Mar 15;178(6):3418-26 [17339436.001]
  • (PMID = 19498463.001).
  • [ISSN] 1469-3178
  • [Journal-full-title] EMBO reports
  • [ISO-abbreviation] EMBO Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Mitogens; 0 / NCR1 protein, human; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Natural Cytotoxicity Triggering Receptor 1; 0 / Phytohemagglutinins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2726665
  •  go-up   go-down


92. Cui G, Kim SJ, Choi SH, Nam H, Cha GS, Paeng KJ: A disposable amperometric sensor screen printed on a nitrocellulose strip: a glucose biosensor employing lead oxide as an interference-removing agent. Anal Chem; 2000 Apr 15;72(8):1925-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A disposable amperometric sensor screen printed on a nitrocellulose strip: a glucose biosensor employing lead oxide as an interference-removing agent.
  • A new type of disposable amperometric sensor is devised by screen printing thick-film electrodes directly on a porous nitrocellulose (NC) strip.
  • The proposed NC/PbO2 strip sensor is shown to be virtually insusceptible to interfering species such as acetaminophen and ascorbic and uric acids and to exhibit good performance, in terms of the sensor-to-sensor reproducibility (standard deviation, +/-0.026 - +/-0.086 microA), the sensitivity (slope, -0.183 microA/mM), and the linearity (correlation coefficient, 0.994 in the range of 0-10 mM).
  • [MeSH-minor] Collodion. Indicators and Reagents

  • Hazardous Substances Data Bank. LEAD OXIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. Nitrocellulose .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784163.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Indicators and Reagents; 0 / Oxides; 2P299V784P / Lead; 4IN6FN8492 / lead oxide; 9004-70-0 / Collodion; IY9XDZ35W2 / Glucose
  •  go-up   go-down


93. Li GP, Wang LX, Shen LF: [The role of angelica injection on P-selectin and anti-cardiolipin antibodies in acute pulmonary embolism rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2010 Nov;26(4):498-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the effect of Chinese medicine, Angelica, injection on the expression of P-, E-selectin and anti-cardiolipin antibody in acute pulmonary embolism rats.
  • Plasma was detected by P-, with 4% paraformaldehyde, and paraffin embedded sections were detected by immunohistochemistry for P-, E-selectin and anti-cardiolipin antibodies.
  • [MeSH-major] Antibodies, Anticardiolipin / metabolism. Drugs, Chinese Herbal / pharmacology. P-Selectin / metabolism. Pulmonary Embolism / metabolism
  • [MeSH-minor] Angelica. Animals. Injections. Male. Pneumonia / metabolism. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21329000.001).
  • [ISSN] 1000-6834
  • [Journal-full-title] Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
  • [ISO-abbreviation] Zhongguo Ying Yong Sheng Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Anticardiolipin; 0 / Drugs, Chinese Herbal; 0 / P-Selectin
  •  go-up   go-down


94. Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y: Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther; 2004 Jun;309(3):1282-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite clear detection of CYP3A62, no detectable levels of CYP3A1 and CYP3A2 proteins, as well as those of mRNAs, were found in the intestinal tract.
  • [MeSH-minor] Animals. Base Sequence. Catalysis. Cytochrome P-450 CYP3A. Female. Liver / enzymology. Male. Membrane Proteins / genetics. Membrane Proteins / isolation & purification. Molecular Sequence Data. RNA, Messenger / analysis. Rats. Rats, Sprague-Dawley. Recombinant Proteins / metabolism. Sequence Homology, Nucleic Acid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15004215.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / Cyp3a1 protein, rat; EC 1.14.14.1 / Cyp3a2 protein, rat; EC 1.14.14.1 / Cyp3a62 protein, rat; EC 1.14.14.1 / Cyp3a9 protein, rat; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


95. Colombo AP, Briançon S, Lieto J, Fessi H: Project, design, and use of a pilot plant for nanocapsule production. Drug Dev Ind Pharm; 2001 Nov;27(10):1063-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to find the scale-up parameters necessary for the preparation of nanocapsules (NCs) for pharmaceutical purposes.
  • We wanted to check if classical tools adequate for the pharmaceutical industry and for industrial scale-up purposes according to well-known chemical engineering technique could be used to perform the NC preparation.
  • Experiments were carried out by varying some operative parameters, such as the impeller speed, the agitation duration for the emulsion preparation, and the reagent concentrations.
  • [MeSH-major] Capsules / chemistry. Drug Delivery Systems. Technology, Pharmaceutical / instrumentation. Technology, Pharmaceutical / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11794809.001).
  • [ISSN] 0363-9045
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsules
  •  go-up   go-down


96. Fushiki H, Yoshimoto H, Ikoma T, Ota S: [A trial of biweekly paclitaxel administration in consideration of QOL for advanced or recurrent gynecologic cancer]. Gan To Kagaku Ryoho; 2005 May;32(5):691-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At present there is no oral medicine available which is effective for advanced or recurrent case of elderly patients with gynecologic cancer.
  • We reviewed the effect, side effect and compliance of the medication.
  • The result was only one patient death from PD and the other 10 patients were PR or a state of NC without side effect.
  • In these cases, we thought that a low-dose of biweekly paclitaxel administration was regarded as a therapy to preserve QOL without a serious side effect and a good compliance of medication.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Genital Neoplasms, Female / drug therapy. Paclitaxel / administration & dosage. Quality of Life
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / psychology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / psychology. Uterine Neoplasms / drug therapy. Uterine Neoplasms / psychology

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918575.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


97. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H: Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol; 2002 Oct;54(4):395-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brachial Artery / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Pyridines / pharmacology. Vasodilation / drug effects
  • [MeSH-minor] Adult. Analysis of Variance. Blood Flow Velocity / drug effects. Double-Blind Method. Humans. Male

  • MedlinePlus Health Information. consumer health - Statins.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacokinet. 2000 Aug;39(2):99-116 [10976657.001]
  • [Cites] J Clin Invest. 2000 Jul;106(1):15-24 [10880044.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1349-57 [9841303.001]
  • [Cites] Atherosclerosis. 1998 Apr;137 Suppl:S101-9 [9694549.001]
  • [Cites] J Cardiovasc Pharmacol. 1998 May;31(5):773-8 [9593078.001]
  • [Cites] Int J Clin Pharmacol Ther. 1997 Jun;35(6):255-60 [9208342.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Feb;17(2):265-72 [9081680.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1001-9 [8801446.001]
  • [Cites] Br Heart J. 1995 Sep;74(3):247-53 [7547018.001]
  • [Cites] Lancet. 1994 Nov 19;344(8934):1383-9 [7968073.001]
  • [Cites] Lancet. 1992 Nov 7;340(8828):1111-5 [1359209.001]
  • [Cites] Circulation. 2001 Jan 16;103(2):276-83 [11208689.001]
  • [Cites] Circ Res. 2001 Nov 9;89(10):866-73 [11701613.001]
  • [Cites] Circulation. 2001 Jul 24;104(4):376-9 [11468195.001]
  • [Cites] J Am Coll Cardiol. 2001 Apr;37(5):1351-8 [11300446.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5):617-21 [11065222.001]
  • [Cites] Br J Pharmacol. 2000 Oct;131(3):553-61 [11015307.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1671-8 [9812903.001]
  • (PMID = 12392587.001).
  • [ISSN] 0306-5251
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyridines; AM91H2KS67 / cerivastatin
  • [Other-IDs] NLM/ PMC1874448
  •  go-up   go-down


98. Sansgiry SS, Chanda S, Shringarpure GS: Impact of bilingual product information labels on Spanish-speaking adults' ability to comprehend OTC information. Res Social Adm Pharm; 2007 Dec;3(4):410-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of bilingual product information labels on Spanish-speaking adults' ability to comprehend OTC information.
  • Language may be a barrier in accessing nonprescription medication information for the non-English-speaking population.
  • OBJECTIVE: The objective of this study was to compare consumer-reported ease of use, product knowledge, and intention to purchase over-the-counter (OTC) medications using bilingual Product Information Labels (PILs) and currently available label formats in a sample of Spanish-speaking consumers.
  • METHODS: Participants were randomly selected from Spanish-speaking consumers shopping for OTC medications in pharmacy or grocery stores in Houston, TX.
  • Domains measured in the questionnaires included ease of use, product knowledge, and purchase intention.
  • All responses were measured on a 7-point Likert-type scale.
  • Mean scores from viewing PILs on ease of use, product knowledge, and purchase intention were higher than those from viewing the other label formats.
  • CONCLUSION: Information provided in Spanish on PILs may be very helpful to the Spanish-speaking community when selecting nonprescription medications.
  • Policy makers and health care providers should consider PILs as an effective means of reducing language barriers and providing OTC medication information to the Spanish-speaking population in the United States.
  • [MeSH-major] Drug Labeling. Language. Nonprescription Drugs

  • MedlinePlus Health Information. consumer health - Over-the-Counter Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082876.001).
  • [ISSN] 1551-7411
  • [Journal-full-title] Research in social & administrative pharmacy : RSAP
  • [ISO-abbreviation] Res Social Adm Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nonprescription Drugs
  •  go-up   go-down


99. Tiwari VK, Kulriya PK, Avasthi DK, Maiti P: Radiation-resistant behavior of poly(vinylidene fluoride)/layered silicate nanocomposites. ACS Appl Mater Interfaces; 2009 Feb;1(2):311-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clay platelets act as nucleating agents, and SHI irradiation causes two crystallization temperatures for the samples exposed to high fluences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20353218.001).
  • [ISSN] 1944-8244
  • [Journal-full-title] ACS applied materials & interfaces
  • [ISO-abbreviation] ACS Appl Mater Interfaces
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Muriaux D, Costes S, Nagashima K, Mirro J, Cho E, Lockett S, Rein A: Role of murine leukemia virus nucleocapsid protein in virus assembly. J Virol; 2004 Nov;78(22):12378-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of murine leukemia virus nucleocapsid protein in virus assembly.
  • The retroviral nucleocapsid protein (NC) originates by cleavage of the Gag polyprotein.
  • It is highly basic and contains one or two zinc fingers.
  • Mutations in either the basic residues or the zinc fingers can affect several events of the virus life cycle.
  • They frequently prevent the specific packaging of the viral RNA, affect reverse transcription, and impair virion assembly.
  • In this work, we explore the role of NC in murine leukemia virus (MLV) particle assembly and release.
  • A panel of NC mutants, including mutants of the zinc finger and of a basic region, as well as truncations of the NC domain of Gag, were studied.
  • Several of these mutations dramatically reduce the release of virus particles.
  • A mutant completely lacking the NC domain is apparently incapable of assembling into particles, although its Gag protein is still targeted to the plasma membrane.
  • By electron microscopy on thin sections of virus-producing cells, we observed that some NC mutants exhibit various stages of budding defects at the plasma membrane and have aberrant particle morphology; electron micrographs of cells expressing some of these mutants are strikingly similar to those of cells expressing "late-domain" mutants.
  • However, the defects of NC mutants with respect to virus release and infectivity could be complemented by an MLV lacking the p12 domain.
  • Therefore, the functions of NC in virus budding and infectivity are completely distinct from viral late-domain function.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1993 Nov;67(11):6487-98 [8411352.001]
  • [Cites] Arch Virol Suppl. 1994;9:513-22 [8032280.001]
  • [Cites] J Virol. 1994 Sep;68(9):6124-9 [8057495.001]
  • [Cites] J Virol. 1995 Oct;69(10):6487-97 [7666550.001]
  • [Cites] J Mol Biol. 1995 Dec 8;254(4):523-37 [7500330.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7577-81 [8755517.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;214:177-218 [8791728.001]
  • [Cites] J Biol Chem. 1996 Dec 27;271(52):33686-92 [8969239.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2902-10 [9207041.001]
  • [Cites] J Virol. 1997 Sep;71(9):6765-76 [9261401.001]
  • [Cites] J Virol. 1997 Sep;71(9):6940-6 [9261422.001]
  • [Cites] J Virol. 1998 Apr;72(4):2723-32 [9525590.001]
  • [Cites] Trends Biochem Sci. 1998 Aug;23(8):297-301 [9757830.001]
  • [Cites] J Virol. 1998 Nov;72(11):9034-44 [9765448.001]
  • [Cites] Virology. 1998 Nov 10;251(1):141-57 [9813210.001]
  • [Cites] J Virol. 1999 Mar;73(3):2270-9 [9971810.001]
  • [Cites] Hum Gene Ther. 1999 Jan 1;10(1):5-14 [10022526.001]
  • [Cites] J Virol. 1999 May;73(5):4251-6 [10196321.001]
  • [Cites] J Virol. 1999 May;73(5):4485-8 [10196352.001]
  • [Cites] J Virol. 1999 Aug;73(8):6670-9 [10400764.001]
  • [Cites] EMBO J. 1999 Sep 1;18(17):4700-10 [10469649.001]
  • [Cites] J Virol. 2000 Apr;74(7):3046-57 [10708419.001]
  • [Cites] J Virol. 2000 Aug;74(15):6734-40 [10888611.001]
  • [Cites] J Virol. 2000 Aug;74(16):7238-49 [10906178.001]
  • [Cites] J Virol. 2000 Aug;74(16):7250-60 [10906179.001]
  • [Cites] J Virol. 2001 Jan;75(1):115-24 [11119580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5246-51 [11320254.001]
  • [Cites] RNA. 2001 Apr;7(4):576-84 [11345436.001]
  • [Cites] J Virol. 2002 May;76(10):4679-87 [11967285.001]
  • [Cites] J Virol. 2002 Nov;76(22):11405-13 [12388701.001]
  • [Cites] J Virol. 2002 Dec;76(23):11853-65 [12414928.001]
  • [Cites] Trends Cell Biol. 2002 Dec;12(12):569-79 [12495845.001]
  • [Cites] EMBO J. 2003 Apr 1;22(7):1707-15 [12660176.001]
  • [Cites] J Virol. 2003 May;77(10):5547-56 [12719547.001]
  • [Cites] J Virol. 2003 Sep;77(17):9388-98 [12915554.001]
  • [Cites] J Virol. 2004 Jan;78(2):716-23 [14694103.001]
  • [Cites] J Virol. 2004 Feb;78(3):1411-20 [14722296.001]
  • [Cites] Virology. 1973 Apr;52(2):456-67 [4705382.001]
  • [Cites] J Mol Appl Genet. 1982;1(4):327-41 [6286831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(22):8420-4 [3141927.001]
  • [Cites] Cell. 1989 Oct 6;59(1):103-12 [2676191.001]
  • [Cites] J Virol. 1992 Aug;66(8):5127-32 [1629968.001]
  • [Cites] J Gen Virol. 1992 Dec;73 ( Pt 12):3079-86 [1469349.001]
  • [Cites] J Virol. 1993 Sep;67(9):5163-74 [8350394.001]
  • [Cites] J Virol. 1993 Sep;67(9):5443-9 [8350405.001]
  • (PMID = 15507624.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01 CO 12400
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, gag; 0 / Nucleocapsid Proteins
  • [Other-IDs] NLM/ PMC525092
  •  go-up   go-down






Advertisement